LeMaitre Vascular (LMAT) 10-K 21 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 13, 2014	Jun. 28, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Registrant Name	'LEMAITRE VASCULAR INC	'	'
Entity Central Index Key	'0001158895	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Common Stock, Shares Outstanding	'	15,579,447	'
Entity Public Float	'	'	$55,483,470

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$14,711	$16,448
Accounts receivable, net of allowances of $263 at December 31, 2013, and $326 at December 31, 2012	10,590	9,048
Inventory	13,255	10,859
Prepaid expenses and other current assets	3,169	2,776
Total current assets	41,725	39,131
Property and equipment, net	5,810	4,544
Goodwill	15,031	13,749
Other intangibles, net	6,144	5,191
Deferred tax assets	1,615	273
Other assets	167	172
Total assets	70,492	63,060
Current liabilities:	'	'
Accounts payable	1,235	1,060
Accrued expenses	7,993	6,777
Acquisition-related obligations	992	557
Total current liabilities	10,220	8,394
Deferred tax liabilities	3,461	1,673
Other long-term liabilities	249	105
Total liabilities	13,930	10,172
Commitments and contingencies (Note 8)	'	'
Stockholders' equity:	'	'
Preferred stock, $0.01 par value; authorized 3,000,000 shares; none outstanding	'	'
Common stock, $0.01 par value; authorized 37,000,000 shares; issued 16,959,330 shares at December 31, 2013, and 16,539,621 shares at December 31, 2012	170	165
Additional paid-in capital	65,354	64,694
Accumulated deficit	-667	-3,869
Accumulated other comprehensive loss	-253	-433
Treasury stock, at cost; 1,380,119 shares at December 31, 2013, and 1,323,537 shares at December 31, 2012	-8,042	-7,669
Total stockholders' equity	56,562	52,888
Total liabilities and stockholders' equity	$70,492	$63,060

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Statement Of Financial Position [Abstract]	'	'
Accounts receivable, allowances	$263	$326
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares outstanding	'	'
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	37,000,000	37,000,000
Common stock, shares issued	16,959,330	16,539,621
Treasury stock, at cost	1,380,119	1,323,537

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Statement [Abstract]	'	'	'
Net sales	$64,549	$56,735	$57,685
Cost of sales	19,434	15,867	17,458
Gross profit	45,115	40,868	40,227
Sales and marketing	22,143	20,811	19,375
General and administrative	12,576	10,973	11,228
Research and development	5,243	5,092	4,425
Medical device excise tax	635	'	'
Restructuring charges	'	'	2,161
Gain on divestitures	'	-248	-735
Impairment charges	'	'	83
Total operating expenses	40,597	36,628	36,537
Income from operations	4,518	4,240	3,690
Other income (expense):	'	'	'
Interest income	4	78	11
Interest expense	-12	-1	'
Foreign currency gain (loss)	-182	-324	51
Income before income taxes	4,328	3,993	3,752
Provision for income taxes	1,126	1,422	1,609
Net income	$3,202	$2,571	$2,143
Earnings per share of common stock:	'	'	'
Basic	$0.21	$0.17	$0.14
Diluted	$0.20	$0.16	$0.13
Weighted-average shares outstanding:	'	'	'
Basic	15,317	15,194	15,458
Diluted	15,764	15,638	15,989
Cash dividends declared per common share	$0.12	$0.10	$0.08

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Comprehensive Income Net Of Tax [Abstract]	'	'	'
Net income	$3,202	$2,571	$2,143
Other comprehensive income:	'	'	'
Foreign currency translation adjustment, net	180	173	-177
Total other comprehensive income	180	173	-177
Comprehensive income	$3,382	$2,744	$1,966

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasury Stock [Member]
In Thousands, except Share data
Beginning Balance at Dec. 31, 2010	$52,356	$161	$64,642	($8,583)	($429)	($3,435)
Beginning Balance, Shares at Dec. 31, 2010	'	16,117,201	'	'	'	637,916
Net income	2,143	'	'	2,143	'	'
Other comprehensive income	-177	'	'	'	-177	'
Issuance of common stock for stock options exercised	68	1	67	'	'	'
Issuance of common stock for stock options exercised, Shares	'	56,751	'	'	'	'
Vested restricted stock units	1	1	'	'	'	'
Vested restricted stock units, shares	'	129,203	'	'	'	'
Excess tax benefits from stock-based compensation awards	50	'	50	'	'	'
Stock based compensation expense	1,097	'	1,097	'	'	'
Repurchase of common stock at cost	-2,213	'	'	'	'	-2,213
Repurchase of common stock at cost, shares	'	'	'	'	'	337,784
Common stock cash dividend paid	-1,237	'	-1,237	'	'	'
Ending Balance at Dec. 31, 2011	52,088	163	64,619	-6,440	-606	-5,648
Ending Balance, Shares at Dec. 31, 2011	'	16,303,155	'	'	'	975,700
Net income	2,571	'	'	2,571	'	'
Other comprehensive income	173	'	'	'	173	'
Issuance of common stock for stock options exercised	358	1	357	'	'	'
Issuance of common stock for stock options exercised, Shares	'	113,207	'	'	'	'
Vested restricted stock units	1	1	'	'	'	'
Vested restricted stock units, shares	'	123,259	'	'	'	'
Excess tax benefits from stock-based compensation awards	23	'	23	'	'	'
Stock based compensation expense	1,213	'	1,213	'	'	'
Repurchase of common stock at cost	-2,021	'	'	'	'	-2,021
Repurchase of common stock at cost, shares	'	'	'	'	'	347,837
Common stock cash dividend paid	-1,518	'	-1,518	'	'	'
Ending Balance at Dec. 31, 2012	52,888	165	64,694	-3,869	-433	-7,669
Ending Balance, Shares at Dec. 31, 2012	'	16,539,621	'	'	'	1,323,537
Net income	3,202	'	'	3,202	'	'
Other comprehensive income	180	'	'	'	180	'
Issuance of common stock for stock options exercised	1,218	4	1,214	'	'	'
Issuance of common stock for stock options exercised, Shares	307,425	307,425	'	'	'	'
Vested restricted stock units	1	1	'	'	'	'
Vested restricted stock units, shares	'	112,284	'	'	'	'
Excess tax benefits from stock-based compensation awards	31	'	31	'	'	'
Stock based compensation expense	1,253	'	1,253	'	'	'
Repurchase of common stock at cost	-373	'	'	'	'	-373
Repurchase of common stock at cost, shares	'	'	'	'	'	56,582
Common stock cash dividend paid	-1,838	'	-1,838	'	'	'
Ending Balance at Dec. 31, 2013	$56,562	$170	$65,354	($667)	($253)	($8,042)
Ending Balance, Shares at Dec. 31, 2013	'	16,959,330	'	'	'	1,380,119

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Operating activities	'	'	'
Net income	$3,202	$2,571	$2,143
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'
Depreciation and amortization	2,793	2,234	2,037
Stock-based compensation	1,253	1,213	1,097
Accrued contingent earnout	57	'	'
Impairment charges	'	'	83
Provision for losses in accounts receivable	-29	153	56
Provision for inventory write-downs	479	863	1,011
Provision (benefit) for deferred income taxes	287	287	1,159
Gain on divestitures	'	-248	-735
Excess tax benefits from stock-based compensation awards	-31	-23	-50
Loss on disposal of property and equipment	52	8	30
Non cash restructuring charges	'	'	732
Foreign currency transaction gain (loss)	115	369	-156
Changes in operating assets and liabilities:	'	'	'
Accounts receivable	-1,247	-640	-174
Inventory	-2,168	-3,725	-998
Prepaid expenses and other assets	-236	303	105
Accounts payable and other liabilities	861	1,357	-3,170
Net cash provided by operating activities	5,388	4,722	3,170
Investing activities	'	'	'
Purchases of property and equipment	-2,733	-1,209	-2,021
Payments related to acquisitions	-3,291	-4,373	-1,151
Receipts related to divestitures	'	500	1,414
Purchase of intellectual property	-164	-116	-64
Net cash used in investing activities	-6,188	-5,198	-1,822
Financing activities	'	'	'
Proceeds from issuance of common stock	1,219	359	69
Purchase of treasury stock	-373	-2,021	-2,213
Excess tax benefits from stock-based compensation awards	31	23	50
Common stock cash dividend paid	-1,838	-1,518	-1,237
Payments of Italian government loan and grant	'	'	-469
Net cash used in financing activities	-961	-3,157	-3,800
Effect of exchange rate changes on cash and cash equivalents	24	-51	-30
Net decrease in cash and cash equivalents	-1,737	-3,684	-2,482
Cash and cash equivalents at beginning of year	16,448	20,132	22,614
Cash and cash equivalents at end of year	$14,711	$16,448	$20,132

Significant_Accounting_Policie

Significant Accounting Policies and Related Matters	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies and Related Matters	'
	1. Significant Accounting Policies and Related Matters
	Description of Business
	Unless the context requires otherwise, references to LeMaitre Vascular, we, our, and us refer to LeMaitre Vascular, Inc. and our subsidiaries. We develop, manufacture, and market medical devices and implants used primarily in the field of vascular surgery. We operate in a single segment in which our principal product lines include the following: valvulotomes, balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. Our offices are located in Burlington, Massachusetts; Mississauga, Canada; Sulzbach, Germany; Milan, Italy; Madrid, Spain; Melbourne, Australia and Tokyo, Japan.
	Consolidation and Basis of Presentation
	Our consolidated financial statements include the accounts of LeMaitre Vascular and the accounts of our wholly-owned subsidiaries, LeMaitre Vascular GmbH, LeMaitre Vascular GK, Vascutech Acquisition LLC, LeMaitre Acquisition LLC, LeMaitre Vascular SAS, LeMaitre Vascular S.r.l., LeMaitre Vascular Spain SL, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LeMaitre Vascular AS, and LeMaitre Vascular Pty Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation.
	Foreign Currency Translation
	Balance sheet accounts of foreign subsidiaries are translated into U.S. dollars at year-end exchange rates. Operating accounts are translated at average exchange rates for each year. Net translation gains or losses are adjusted directly to a separate component of other comprehensive income (loss) within stockholders’ equity. Foreign exchange transaction gains (losses), substantially all of which relate to intercompany activity between us and our foreign subsidiaries, are included in other income (expense) in the accompanying consolidated statements of operations.
	Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to bad debts, inventories, intangible assets, sales returns and discounts, and income taxes are reviewed on an ongoing basis and updated as appropriate. Actual results could differ from those estimates.
	Revenue Recognition
	Our revenue is derived primarily from the sale of disposable or implantable devices used during vascular surgery. We sell primarily directly to hospitals and to a lesser extent to distributors, as described below, and, during the periods presented in our consolidated financial statements, entered into consigned inventory arrangements with either hospitals or distributors on a limited basis.
	We recognize revenue when four basic criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. We assess whether the fee is fixed or determinable based on the terms of the agreement associated with the transaction. Sales transactions are based on prices that are determinable at the time the customer’s purchase order is accepted by us. Orders that are not accompanied with a purchase order are either confirmed in writing or verbally with the customer.
	After the delivery of the product, there is no uncertainty about customer acceptance due to the nature of the product. There is no contingency for acceptance, warranty, or price protection. We do not recognize revenue on consigned sales until the customer notifies us that the products have been used. In order to determine whether collection is reasonably assured, we assess a number of factors, including past transaction history with the customer and the creditworthiness of the customer. If we determine that collection is not reasonably assured, we defer the recognition of revenue until collection becomes reasonably assured, which is generally upon receipt of payment. We provide for product returns at the time revenue is recognized based on our product return history.
	Based on these policies, we recognize revenue, net of allowances for returns and discounts, as products are shipped, based on shipping point terms, or at the time consigned inventory is consumed at which time title passes to customers. We recognize revenue net of allowances for returns and discounts, at the time of shipment of our products to our distributors. Customers returning products are entitled to full or partial credit based on the condition and timing of the return. To be accepted, a returned product must be unopened (if sterile), unadulterated, and undamaged, must have at least 18 months remaining prior to its expiration date, or twelve months for our hospital customers in Europe, and generally be returned within 30 days of shipment. These return policies apply to sales to both hospitals and distributors. The amount of products returned to us, either for exchange or credit, has not been material. Nevertheless, we provide for an allowance for future sales returns based on historical return experience. Our cost of replacing defective products has not been material and is accounted for at the time of replacement.
	Research and Development Expense
	Research and development costs, principally salaries, laboratory testing, and supplies, are expensed as incurred and also include royalty payments associated with licensed and acquired intellectual property.
	Shipping and Handling Costs
	Shipping and handling fees paid by customers are recorded within net sales, with the related expense recorded in cost of sales.
	Advertising Costs
	Advertising costs are expensed as incurred and are included as a component of sales and marketing expense in the accompanying consolidated statements of operations. Advertising costs are as follows:
		Year ended December 31,
		2013		2012		2011
				(in thousands)
	Advertising expense	$	421	$	717	$	410
	Cash and Cash Equivalents
	We consider all highly liquid instruments purchased with maturity dates of 90 days or less to be cash equivalents. Cash and cash equivalents are primarily invested in money market funds. These amounts are stated at cost, which approximates fair value.
	Concentrations of Credit Risk
	Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, accounts receivable, and notes receivable. Cash equivalents represent highly liquid investments with maturities of 90 days or less at the date of purchase. Marketable securities are investment grade, interest-earning securities and are diversified by type and industry. Credit risk related to cash, cash equivalents, and marketable securities are limited based on the creditworthiness of the financial institutions at which these funds are held. Credit risk related to notes receivable is assessed based upon the individual payor as of the original fair value determination and updated periodically as required.
	Our accounts receivable are with customers based in the United States and internationally. Accounts receivable generally are due within 30 to 90 days of invoice and are stated at amounts due from customers, net of an allowance for doubtful accounts and sales returns, other than in certain European markets where longer payment terms are customary and may range from 90 to 240 days. We perform ongoing credit evaluations of the financial condition of our customers and adjust credit limits based upon payment history and the current creditworthiness of the customers, as determined by a review of their current credit information. We continuously monitor aging reports, collections, and payments from customers, and maintain a provision for estimated credit losses based upon historical experience and any specific customer collection issues we identify.
	We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our European sales to government-owned or supported customers such as hospitals, distributors and agents, in Southern Europe, specifically Italy and Spain may be subject to significant payment delays due to government austerity measures impacting funding and payment practices. As of December 31, 2013 our receivables in Italy and Spain totaled $1.2 million and $0.5 million, respectively. Receivables balances with certain publicly-owned hospitals and government supported customers in these countries can accumulate over a period of time and then subsequently be settled as large lump sum payments. While we believe our allowance for doubtful accounts in these countries is adequate as of December 31, 2013, if significant changes were to occur in the payment practices of these European governments or if government funding becomes unavailable, we may not be able to collect on receivables due to us from these customers and our write offs of uncollectible amounts may increase.
	We write off accounts receivable when they become uncollectible. Such credit losses have historically been within our expectations and allowances. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable. We review our allowance for doubtful accounts on a monthly basis and all past due balances are reviewed individually for collectability. The provision for the allowance for doubtful accounts is recorded in general and administrative expenses. The following is a summary of our allowance for doubtful accounts and sales returns:
		Balance at		Additions		Deductions		Balance
		Beginning		Charged to		from		at End of
		of Period		Income		Reserves		Period
		(in thousands)
	Allowance for doubtful accounts and sales returns:
	Year ended December 31, 2013	$	326	$	29	$	92	$	263
	Year ended December 31, 2012		211		153		38		326
	Year ended December 31, 2011		184		56		29		211
	Fair Value of Financial Instruments
	Our financial instruments include cash and cash equivalents, marketable securities, accounts receivable, trade payables, and notes payable. The fair value of the majority of these instruments approximates their carrying value based upon their short-term nature or variable rates of interest.
	Inventory
	Inventory consists of finished products, work-in-process, and raw materials. We value inventory at the lower of cost or market value. Cost includes materials, labor, and manufacturing overhead and is determined using the first-in, first-out (FIFO) method. On a quarterly basis, we review inventory quantities on hand and analyze the provision for excess and obsolete inventory based primarily on product expiration dating and our estimated sales forecast, which is based on sales history and anticipated future demand. Our estimates of future product demand may not be accurate, and we may understate or overstate the provision required for excess and obsolete inventory. Accordingly, any significant unanticipated changes in demand could have a significant impact on the value of our inventory and results of operations.
	Property and Equipment
	Property and equipment are recorded at cost. Depreciation is provided over the estimated useful lives of the related assets using straight-line method as follows:
	Description	Useful Life
	Computers and equipment	3–5 years
	Machinery and equipment	3–10 years
	Leasehold improvements	The shorter of its useful life or lease term
	Expenditures for maintenance and repairs are charged to operations when incurred, while additions and betterments are capitalized. When assets are retired or disposed, the asset’s original cost and related accumulated depreciation are eliminated from the accounts and any gain or loss is reflected in the statement of operations.
	Valuation of Business Combinations
	We assign the value of the consideration transferred to acquire a business to the tangible assets and identifiable intangible assets acquired and liabilities assumed on the basis of their fair values at the date of acquisition. We assess the fair value of assets, including intangible assets, using a variety of methods and are usually performed by an independent appraiser who measures fair value from the perspective of a market participant.
	Acquisitions have been accounted for using the acquisition method, and the acquired companies’ results have been included in the accompanying consolidated financial statements from their respective dates of acquisition. Acquisition transaction costs have been recorded in general and administrative expenses, and are expensed as incurred. Allocation of the purchase price for acquisitions is based on estimates of the fair value of the net assets acquired and, for acquisitions completed within the past year, is subject to adjustment upon finalization of the purchase price allocation.
	Our acquisitions have historically been made at prices above the fair value of the acquired assets, resulting in goodwill, due to expectations of synergies of combining the businesses. These synergies include use of our existing commercial infrastructure to expand sales of the acquired businesses’ products, use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of our products, and the elimination of redundant facilities, functions and staffing.
	Contingent Consideration
	The Financial Accounting Standards Board (the FASB) requires contingent consideration be recognized at the date of acquisition, based on the fair value at that date, and then re-measured periodically through adjustments to net income.
	Impairment of Long-lived Assets
	We review our long-lived assets (primarily property and equipment and intangible assets) subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall, or an adverse action or assessment by a regulator. If an impairment indicator exists, we test the intangible asset for recoverability. We record impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. Impairment is measured based on the fair market value of the affected asset using discounted cash flows.
	In 2011, we determined that certain patents within our portfolio in the United States and Europe had no value based upon an analysis of expected economic benefits. As a result, we recorded an impairment charge of $0.1 million for the write-down of these patents.
	This impairment adjustment falls within Level 3 of the fair value hierarchy, due to the use of significant unobservable inputs to determine fair value. The fair value measurements were calculated using unobservable inputs, primarily using the income approach, specifically the discounted cash flow method. The amount and timing of future cash flows within our analysis was based on our most recent operational budgets, long range strategic plans and other estimates.
	Goodwill
	Goodwill represents the amount of consideration paid in connection with business acquisitions in excess of the fair value of assets acquired and liabilities assumed. Goodwill is evaluated for impairment annually or more frequently if indicators of impairment are present or changes in circumstances suggest that an impairment may exist. We evaluate the December 31 balance of the carrying value of goodwill based on a single reporting unit annually. We perform an assessment of qualitative factors to determine if it is “more likely than not” that the fair value of our reporting unit is less than its carrying value as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. The “more likely than not” threshold is defined as having a likelihood of more than 50 percent. If required, the next step of the goodwill impairment test is to determine the fair value of the reporting unit. The implied fair value of goodwill is determined on the same basis as the amount of goodwill recognized in connection with a business combination. Specifically, the fair value of a reporting unit is allocated to all of the assets and liabilities (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination as of the date of the impairment review and as if the fair value of the reporting unit was the price paid to acquire the reporting unit. The excess of the fair value of a reporting unit over the amounts assigned to its assets and liabilities is the implied fair value of goodwill. If the carrying amount of the reporting unit goodwill exceeds the implied fair value of that goodwill, an impairment loss shall be recognized in an amount equal to that excess. We have determined that no goodwill impairment charges were required for the years ended December 31, 2013, 2012, or 2011.
	Other Intangible Assets
Other intangible assets consist primarily of patents, trademarks, technology licenses, and customer relationships acquired in connection with business acquisitions and asset acquisitions and are amortized over their estimated useful lives, ranging from 1 to 13 years.
Stock-based Compensation
We recognize, as expense, the estimated fair value of stock options to employees which is determined using the Black-Scholes option pricing model. We have elected to recognize the compensation cost of all share-based awards on a straight-line basis over the vesting period of the award. In periods that we grant stock options, fair value assumptions are based on volatility, interest, dividend yield, and expected term over which the stock options will be outstanding. The computation of expected volatility is based on the historical volatility of the company’s stock. The interest rate for periods within the contractual life of the award is based on the U.S. Treasury risk-free interest rate in effect at the time of grant. Historical data on exercise patterns is the basis for estimating the expected life of an option. The expected annual dividend rate was calculated by dividing our annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date.
We also issue restricted stock units (RSUs) as an additional form of equity compensation to our employees, officers, and directors, pursuant to our stockholder-approved 2006 Plan. RSUs entitle the grantee to an issuance of stock at no cost and generally vest over a period of time determined by our Board of Directors at the time of grant based upon the continued service to the company. The fair market value of the award is determined based on the number of RSUs granted and the market value of our common stock on the grant date and is amortized to expense over the period of vesting. Unvested RSUs are forfeited and canceled as of the date that employment or service to the company terminates. RSUs are settled in shares of our common stock upon vesting. We may repurchase common stock upon our employees’ vesting in RSUs in order to cover any minimum tax withholding liability as a result of the RSUs having vested.
Share-based compensation charges are recorded net of the estimated forfeitures based upon historical rates and will be adjusted in future periods to reflect the results of actual forfeitures and vesting. Share-based compensation charges are recorded across the consolidated statement of operations based upon the grantee’s primary function.
Commitments and Contingencies
In the normal course of business, we are subject to proceedings, lawsuits, and other claims and assessments for matters related to, among other things, patent infringement, business acquisitions, employment, and product recalls. We assess the likelihood of any adverse judgments or outcomes to these matters as well as potential ranges of probable losses. A determination of the amount of reserves required, if any, for these contingencies is made after careful analysis of each individual issue. The required reserves may change in the future due to new developments in each matter or changes in approach such as a change in settlement strategy in dealing with these matters. We record charges for the losses we anticipate incurring in connection with litigation and claims against us when we conclude a loss is probable and we can reasonably estimate these losses. During the years ended December 31, 2013, 2012, and 2011, we were not subject to any material litigation or claims and assessments.
Income Taxes
We account for income taxes under the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred taxes are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The provision for income taxes includes taxes currently payable and deferred taxes resulting from the tax effects of temporary differences between the financial statement and tax bases of assets and liabilities. We maintain valuation allowances where it is more likely than not that all or a portion of a deferred tax asset will not be realized. Changes in the valuation allowances are included in our tax provision in the period of change. In determining whether a valuation allowance is warranted, we evaluate factors such as prior earnings history, expected future earnings, carry-back and carry-forward periods and tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset.
We recognize, measure, present and disclose in our financial statements, uncertain tax positions that we have taken or expect to take on a tax return. We recognize in our financial statements the impact of tax positions that meet a “more likely than not” threshold, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement.
Our policy is to classify interest and penalties related to unrecognized tax benefits as income tax expense.
Comprehensive Income
Comprehensive income is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other than reported net income, comprehensive income includes foreign currency translation adjustments, which are disclosed in the accompanying consolidated statements of comprehensive income. There were no reclassifications out of comprehensive income for the years ended December 31, 2013 and 2012.
Accumulated other comprehensive loss consisted of foreign currency translation adjustment losses of $0.3 million and $0.4 million as of December 31, 2013 and 2012, respectively.
Restructuring
We record restructuring charges incurred in connection with consolidation or relocation of operations, exited business lines, reductions in force, or distributor terminations. These restructuring charges, which reflect our commitment to a termination or exit plan that will begin within twelve months, are based on estimates of the expected costs associated with site closure, legal matters, contract terminations, severance payments, or other costs directly related to the restructuring. If the actual cost incurred exceeds the estimated cost, an additional charge to earnings will result. If the actual cost is less than the estimated cost, a credit to earnings will be recognized.
Earnings per Share
We compute basic earnings per share by dividing net income available for common stockholders by the weighted average number of shares outstanding during the year. Except where the result would be anti-dilutive to net income per share, diluted earnings per share has been computed using the treasury stock method and reflects the potential vesting of restricted common stock and the potential exercise of stock options, as well as their related income tax effects.
The computation of basic and diluted net income per share is as follows:
	Year ended December 31,
	2013		2012		2011
	(in thousands, except per share data)
Basic:
Net income available for common stockholders	$	3,202	$	2,571	$	2,143
Weighted average shares outstanding		15,317		15,194		15,458
Basic earnings per share	$	0.21	$	0.17	$	0.14
Diluted:
Net income available for common stockholders	$	3,202	$	2,571	$	2,143
Weighted-average shares outstanding		15,317		15,194		15,458
Common stock equivalents, if dilutive		447		444		531
Shares used in computing diluted earnings per common share		15,764		15,638		15,989
Diluted earnings per share	$	0.2	$	0.16	$	0.13
Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive		373		549		355
Recent Accounting Pronouncements
In February 2013, the FASB issued new guidance which requires disclosure of changes in accumulated other comprehensive income balances by component and significant reclassification adjustments from accumulated other comprehensive income in a single note or on the face of the financial statements. This guidance became effective January 1, 2013. The adoption of this standard, which is related to disclosure only, did not have an impact on our results of operations or financial position.
In July 2013, the FASB issued guidance to address the diversity in practice related to the financial statement presentation of unrecognized tax benefits as either a reduction of a deferred tax asset or a liability when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of this guidance is not expected to have a material impact on our consolidated financial statements.

Acquisitions_and_Divestitures

Acquisitions and Divestitures	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Acquisitions and Divestitures	'
	2. Acquisitions and Divestitures
	XenoSure Manufacturing and Distribution Rights
	In October 2012, we entered into an Asset Purchase Agreement (the Neovasc Agreement) with Neovasc, Inc. and its subsidiary, Neovasc Medical Inc. (collectively Neovasc) to acquire the manufacturing and distribution rights of the XenoSure biologic vascular patch. Previously, we were the exclusive distributor of the XenoSure biologic vascular patch through January 26, 2016 and held an option to purchase the manufacturing and distribution rights. Assets acquired in October 2012 include intellectual property, manufacturing know-how, and a five year non-compete agreement. Other provisions of the Neovasc Agreement include transitional assistance from Neovasc and mutual indemnification for losses arising out of or relating to certain breaches of, and misrepresentations under, the Neovasc Agreement. Additionally, we have entered into a supply agreement with Neovasc while we transition manufacturing to our Burlington facility.
	The purchase price for this acquisition was $4.6 million. We paid Neovasc $4.3 million at the closing of the acquisition. We paid the remaining $0.3 million in October 2013. We accounted for the acquisition as a business combination. The following table summarizes the final purchase accounting for the fair value of the assets acquired and liabilities assumed at the date of the acquisition:
		Allocated
		Fair Value
		(in thousands)
	Current Assets	$	12
	Intangible assets		2,756
	Goodwill		1,832
	Total assets acquired		4,600
	Total liabilities assumed		—
		$	4,600
	The goodwill of $1.8 million will be deductible for tax purposes over 15 years.
	Of the $2.8 million of acquired intangible assets, the following table reflects the allocation of the acquired intangible assets and related estimated useful lives:
		Allocated			Weighted
		Fair Value			Average
					Useful Life
		(in thousands)
	Patents	$	2,450			13.0 years
	Non-compete agreement		306			5.0 years
	Total intangible assets	$	2,756
	Clinical Instruments International, Inc.
	In July 2013, we entered into an Asset Purchase Agreement with Clinical Instruments International, Inc. (Clinical Instruments) to acquire substantially all the assets of Clinical Instruments for $1.1 million. We paid $0.9 million at the closing and the remaining $0.2 million is payable in October 2014. We accounted for the acquisition as a business combination. Assets acquired include inventory and intellectual property.
	The following table summarizes the fair value of the assets acquired and liabilities assumed at the date of the acquisition:
		Allocated
		Fair Value
		(in thousands)
	Current assets	$	169
	Intangible assets		322
	Goodwill		614
	Total assets acquired		1,105
	Total liabilities assumed		—
		$	1,105
	The goodwill of $0.6 million will be deductible for tax purposes over 15 years.
	Of the $0.3 million of acquired intangible assets, the following table reflects the allocation of the acquired intangible assets and related estimated useful lives:
		Allocated			Weighted
		Fair Value			Average
					Useful Life
		(in thousands)
	Non-compete agreement	$	95			5.0 years
	Technology	$	147			6.0 years
	Customer relationships		80			6.0 years
	Total intangible assets	$	322
	InaVein, LLC
	In August 2013, we entered into an Asset Purchase Agreement with InaVein, LLC (InaVein) to acquire substantially all the assets of InaVein for $2.5 million and acquisition-related contingent consideration totaling $1.4 million in 2014 and 2015 dependent on the sales performance of the acquired business and the timing of regulatory approval in China. We paid $2.1 million at the closing and the remaining $0.4 million is payable in August 2014. We accounted for the acquisition as a business combination. Assets acquired include receivables, inventory, equipment, and intellectual property. Liabilities assumed include payables and service contracts.
	The following table summarizes the fair value of the assets acquired and liabilities assumed at the date of the acquisition:
		Allocated
		Fair Value
		(in thousands)
	Current assets	$	670
	Property and equipment, net		154
	Intangible assets		1,143
	Goodwill		668
	Total assets acquired		2,635
	Total liabilities assumed		(100	)
		$	2,535
	The goodwill of $0.7 million will be deductible for tax purposes over 15 years.
	Of the $1.1 million of acquired intangible assets, the following table reflects the allocation of the acquired intangible assets and related estimated useful lives:
		Allocated			Weighted
		Fair Value			Average
					Useful Life
		(in thousands)
Non-compete agreement	$	70			5.0 years
Tradename		163			8.0 years
Technology		354			6.0 years
Customer relationships		556			7.0 years
Total intangible assets	$	1,143
We recorded $42,000 as the fair value of contingent consideration at the acquisition date and an additional $57,000 as a charge to general and administrative expense in 2013.
Schaublin Medica SA Distribution Agreement
In October 2012, we entered into a definitive agreement with Schaublin Medica SA (Schaublin) to terminate its distribution of our products in Switzerland and to acquire certain assets and rights from Schaublin effective as of January 1, 2013 for $0.2 million. The purchase price was paid in three equal installments in October 2012, January 2013, and January 2014. We recorded $0.1 million of intangible assets and recognized a $0.1 million of transition services as selling expense. We allocated the payment to the tangible and intangible assets acquired based on the estimated fair value of each of these elements to the transaction. The weighted-average amortization period for these intangibles as of December 31, 2012 was 7.0 years.
TryTech Distribution Agreement
In December 2012, we entered into a definitive agreement with TryTech Corporation (TryTech) to terminate its distribution of our products in a certain Japanese territory and to acquire certain assets and rights from TryTech effective as of April 1, 2013 for $0.1 million. The purchase price is due in three equal installments with payments made in December 2012 and March 2013 with the final payment due in March 2014. We recorded $0.1 million of intangible assets and recognized $20,000 of transition services as selling expense. We allocated the payment to the tangible and intangible assets acquired based on the estimated fair value of each of these elements to the transaction. The weighted-average amortization period for these intangibles as of December 31, 2012 was 3.0 years.
Medistim Norge AS Distribution Agreement
In October 2013, we entered into a definitive agreement with Medistim Norge AS (Medistim) to terminate its distribution of our products in Norway and to acquire certain assets and rights from Medistim effective as of January 1, 2014 for $0.2 million. The purchase price is due in three installments with payments made in October 2013 and January 2014 with the final payment due in December 2014. We allocated the payment to the tangible and intangible assets acquired based on the estimated fair value of each of these elements to the transaction. The weighted-average amortization period for these intangibles as of December 31, 2013 was 3.5 years.
Tag Medical Pty Ltd Distribution Agreement
In October 2013, we entered into a definitive agreement with Tag Medical Pty Ltd (Tag) to terminate its distribution of our products in Australia and to acquire certain assets and rights from Tag effective as of January 1, 2014 for $0.2 million. The purchase price is due in three installments with payments made in November 2013 and January 2014 and the final payment due in December 2014. We allocated the payment to the tangible and intangible assets acquired based on the estimated fair value of each of these elements to the transaction. The weighted-average amortization period for these intangibles as of December 31, 2013 was 4.8 years.
OptiLock Implantable Port
On June 1, 2010, we sold our OptiLock Implantable Port product line to Minvasive Ltd. (Minvasive). In exchange for consideration of approximately $0.2 million, Minvasive received our existing inventory, tangible and intangible assets, and a customer list associated with the product line. Payment terms included $30,000 due at signing, with the remaining balance to be paid in the form of a royalty on future sales. In May 2012, Minvasive provided notice that it was filing for insolvency protection under German law. As a result, we wrote-off the remaining balance of approximately $52,000 as a loss on divestitures during the three months ended June 30, 2012.
TAArget and UniFit Stent Grafts
On June 30, 2011, we sold our TAArget and UniFit stent graft product lines to Duke Vascular, Inc. (Duke). In exchange for consideration of approximately $0.1 million in cash and a $0.5 million promissory note, Duke received most of our existing inventory, tangible and intangible assets, and a customer list associated with the product lines. In addition, Duke assumed our future obligations associated with the UNITE and ENTRUST clinical trials. We received the initial cash payment on June 30, 2011. The $0.5 million promissory note bore interest at 7% and was payable on June 30, 2012. We recorded the estimated fair value of the promissory note as $0.2 million receivable in other long term assets. As a result of this transaction we recorded a net charge of approximately $0.4 million in cost of sales during the year ended December 31, 2011. In 2012, we received $0.5 million which was applied to the outstanding promissory note balance of $0.2 million, interest income, and as a gain on divestiture of $0.3 million.
Endologix Stent Grafts
On July 6, 2011, we entered into an early termination agreement for our distribution rights of Endologix’s stent graft products in Europe. Under the terms of the agreement, we received $1.3 million in exchange for the early termination of our distribution agreement on August 31, 2011, certain customer contracts, our provision of sales and marketing services, and most of our remaining inventory. Previously, we held distribution rights in certain European countries for Endologix’s stent graft products through June 30, 2013. We recognized a gain of $0.7 million upon the termination of the distribution agreement during the year ended December 31, 2011.
The fair market valuations associated with these transactions fall within Level 3 of the fair value hierarchy, due to the use of significant unobservable inputs to determine fair value. The fair value measurements were calculated using unobservable inputs, primarily using the income approach, specifically the discounted cash flow method. The amount and timing of future cash flows within our analysis was based on our due diligence models, most recent operational budgets, long range strategic plans and other estimates.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventory	'
	3. Inventory
	Inventory consists of the following:
		As of December 31,
		2013		2012
		(in thousands)
	Raw materials	$	3,647	$	2,471
	Work-in-process		2,949		2,084
	Finished products		6,659		6,304
	Total inventory	$	13,255	$	10,859
	We held inventory on consignment of $0.7 million as of December 31, 2013 and 2012.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Property and Equipment	'
	4. Property and Equipment
	Property and equipment consists of the following:
		As of December 31,
		2013			2012
		(in thousands)
	Computers and equipment	$	2,369		$	2,196
	Machinery and equipment		6,570			5,599
	Leasehold improvements		4,104			2,968
	Gross property and equipment		13,043			10,763
	Less accumulated depreciation		(7,233	)		(6,219	)
	Property and equipment, net	$	5,810		$	4,544
	Depreciation expense is as follows:
		Year ended December 31,
		2013			2012			2011
					(in thousands)
	Depreciation expense	$	1,573		$	1,319		$	1,047

Goodwill_and_Other_Intangibles

Goodwill and Other Intangibles	12 Months Ended
	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill and Other Intangibles	'
	5. Goodwill and Other Intangibles
	Goodwill consists of the following:
		As of December 31,
		2013		2012
		(in thousands)
	Balance at beginning of year	$	13,749	$	11,917
	Additions for acquisitions		1,282		1,832
	Balance at end of year	$	15,031	$	13,749
	Other intangibles consist of the following:
		2013						2012
		Gross		Accumulated		Net		Gross		Accumulated		Net
		Carrying		Amortization		Carrying		Carrying		Amortization		Carrying
		Value				Value of		Value				Value of
						Intangible						Intangible
						Assets						Assets
		(in thousands)
	Patents	$	5,679	$	1,932	$	3,747	$	5,108	$	1,339	$	3,769
	Trademarks and technology licenses		1,414		935		479		1,157		821		336
	Customer relationships		2,835		1,441		1,394		1,757		1,001		756
	Other intangible assets		971		447		524		673		343		330
	Total identifiable intangible assets	$	10,899	$	4,755	$	6,144	$	8,695	$	3,504	$	5,191
	These assets are being amortized over useful lives ranging from 1 to 13 years. The weighted-average amortization period for these intangibles as of December 31, 2013, is 6.5 years. Amortization expense is included in general and administrative expense and is as follows:
		Year ended December 31,
		2013		2012		2011
		(in thousands)
	Amortization expense	$	1,220	$	915	$	990
	Estimated amortization expense for each of the five succeeding fiscal years, based upon the intangible assets at December 31, 2013, is as follows:
		Year ended December 31,
		2014		2015		2016		2017		2018
			(in thousands)
	Amortization expense	$	1,414	$	1,015	$	870	$	612	$	497

Financing_Arrangements

Financing Arrangements	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Financing Arrangements	'
	6. Financing Arrangements
	As part of the purchase of Biomateriali S.r.l., we assumed a loan from the Italian government under a program that provided funding to certain businesses in Italy through a combination of grants and loans if certain requirements are met. The loan was stated to be payable in ten annual payments through 2018 of principal and interest at an interest rate of 0.74%. The present value of the loan was recorded as of the date the proceeds were received using our incremental borrowing rate. Interest was being imputed on the loan and the amortization was recorded as interest expense. The loan and grant became due in full as a result of the Biomateriali S.r.l. plant closure. As a result, in December 2011, we incurred approximately $0.1 million of restructuring charges related to additional interest and penalties charges, and we made the final payment to the Italian government of $0.5 million.

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Accrued Expenses	'
	7. Accrued Expenses
	Accrued expenses consist of the following:
		As of December 31,
		2013		2012
		(in thousands)
	Compensation and related taxes	$	4,710	$	3,860
	Income and other taxes		885		963
	Professional fees		428		521
	Other		1,970		1,433
	Total	$	7,993	$	6,777

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	8. Commitments and Contingencies
	Leases
	We conduct certain of our operations in leased facilities, which are accounted for as operating leases. Certain leases include renewal options. In addition, we lease automobiles and equipment under operating leases. There were no assets held under capital leases at December 31, 2013 and 2012. Rent expense was as follows:
		Year ended December 31,
		2013		2012		2011
		(in thousands)
	Rent expense	$	1,264	$	1,030	$	1,182
	At December 31, 2013, the minimum rental commitments under all non-cancelable operating leases with initial or remaining terms of more than one year, for each of the following fiscal years, are as follows:
		Year ended December 31,
		2014		2015		2016		2017		2018		Thereafter
		(in thousands)
	Operating leases	$	1,159	$	1,119	$	914	$	689	$	802	$	4,075
	Purchase Commitments
	As part of our normal course of business, we have purchase commitments to purchase $4.4 million of inventory through 2015. The purchase commitments for inventory are to be used in operations over the normal course of business and do not represent excess commitments or loss contracts.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	9. Income Taxes
	Income (loss) before income taxes is as follows:
		Year ended December 31,
		2013			2012			2011
		(in thousands)
	United States	$	4,692		$	3,918		$	3,511
	Foreign		(364	)		75			241
	Total	$	4,328		$	3,993		$	3,752
	Certain of our foreign subsidiaries are included in the U.S. tax return as branches but are included as foreign for purposes of the table above.
	The provision (benefit) for income taxes is as follows:
		Year ended December 31,
		2013			2012			2011
		(in thousands)
	Current:
	Federal	$	504		$	881		$	309
	State		143			100			9
	Foreign		192			154			132
			839			1,135			450
	Deferred:
	Federal		1,968			503			831
	State		(84	)		12			116
	Foreign		(1,597	)		(228	)		212
			287			287			1,159
	Provision for income taxes	$	1,126		$	1,422		$	1,609
	We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of December 31, 2013, the gross amount of unrecognized tax benefits exclusive of interest and penalties was $0.1 million, which may decrease within the 12 months ending December 31, 2014. We remain subject to examination until the statute of limitations expires for each respective tax jurisdiction. The statute of limitations will be open with respect to these tax positions through 2017. A reconciliation of beginning and ending amount of our unrecognized tax benefits is as follows:
		2013			2012			2011
		(in thousands)
	Unrecognized tax benefits at the beginning of year	$	321		$	329		$	277
	Additions for tax positions of current year		—			—			52
	Additions for tax positions of prior years		—			6			—
	Reductions for lapses of the applicable statutes of limitations		(210	)		(14	)		—
	Unrecognized tax benefits at the end of the year	$	111		$	321		$	329
	Deferred taxes are attributable to the following temporary differences:
		As of December 31,
		2013			2012
		(in thousands)
	Deferred tax assets:
	Inventory	$	824		$	772
	Net operating loss carryforwards		2,190			2,561
	Tax credit carryforwards		551			555
	Reserves and accruals		313			263
	Intangible assets		1,102			916
	Stock options		203			326
	Other		38			288
	Total deferred tax assets		5,221			5,681
	Deferred tax liabilities:
	Property and equipment		(742	)		(692	)
	Goodwill		(2,727	)		(2,374	)
	Foreign branch deferred offset		(1,735	)		(146	)
	Other		—			(26	)
	Total deferred tax liabilities		(5,204	)		(3,238	)
	Net deferred tax assets before valuation allowance		17			2,443
	Valuation allowance		(969	)		(3,053	)
	Net deferred tax liabiltity	$	(952	)	$	(610	)
	Deferred tax classification
	Short-term deferred tax asset	$	932		$	850
	Short-term deferred tax liability		(38	)		(60	)
	Net short-term deferred tax asset	$	894		$	790
	Long-term deferred tax asset	$	1,615		$	273
	Long-term deferred tax liability		(3,461	)		(1,673	)
	Net long-term deferred tax liability	$	(1,846	)	$	(1,400	)
	Net deferred tax liability	$	(952	)	$	(610	)
	We have assessed the need for a valuation allowance against our deferred tax assets and continue to carry a valuation allowance against $1.0 million of foreign deferred tax assets and state credits; based on the weight of available evidence, we believe it is more likely than not such assets will not be realized. The valuation allowance against our deferred tax assets may require adjustment in the future based on changes in the mix of temporary differences, changes in tax laws, and operating performance.
In 2013, we released valuation allowances on certain deferred assets associated with foreign subsidiary historical losses as well as state research and development credits. Our assessment considered evidence such as current profitability, utilization of certain available tax assets and liabilities, and projected future earnings. Based on this evidence, we concluded that it was more likely than not that we would generate sufficient pre-tax income in future periods to utilize all of our deferred tax assets in France and Italy and a portion of our deferred tax assets related to state research and development credits.
Realization of our deferred tax assets is dependent on our generating sufficient taxable income in future periods. Although we believe it is more likely than not that future taxable income will be sufficient to allow us to recover substantially all of the value of our deferred tax assets, realization is not assured and future events could cause us to change our judgment. In the event that actual results differ from our estimates, or we adjust these estimates in the future periods, further adjustments to our valuation allowance may be recorded, which could materially impact our financial position and net income (loss) in the period of the adjustment. As of December 31, 2013, we have net operating loss carryforwards in France of $3.9 million that do not expire, Spain of $1.5 million that begin to expire in 2029, Italy of $1.1 million that do not expire, Sweden of $0.3 million that do not expire, Switzerland of $0.3 million that begin to expire in 2019 and others of $0.1 million that do not expire. We also have Federal and state tax credit carryforwards of approximately $0.9 million that are available to reduce future tax liabilities, which expire at various dates through 2023, or can be carried forward indefinitely. Approximately $0.1 million of these Federal and state tax credits relate to excess stock compensation deductions and as such, the benefit of these tax deductions will be credited to additional paid-in capital when we receive a cash benefit from these credits being utilized. Ownership changes, as defined by the Internal Revenue Code, may limit the amount of net operating losses and research and experimentation credit carryforwards that can be utilized annually to offset future taxable income and taxes payable.
A provision has not been made for U.S. or additional non-U.S. taxes on $1.4 million of undistributed earnings of international subsidiaries that could be subject to taxation if remitted to the U.S. because we plan to keep these amounts permanently reinvested overseas except for instances where we can remit such earnings to the U.S. without an associated net tax cost. However, to the extent such foreign earnings were remitted in the future a deferred tax liability of $0.5 million would be recorded.
In January 2013, legislation was signed into law which retroactively reinstated various tax provisions which had previously expired January 1, 2012, principally related to the Federal R&D credit. As this legislation was enacted in January 2013, our financial statements reflect the effects of the legislation in 2013. Had this tax legislation been enacted in 2012, we would have recognized an additional $0.2 million of additional U.S. tax credits in our consolidated financial statements for the year ending December 31, 2012.
A reconciliation of the Federal statutory rate to our effective tax rate is as follows:
	2013			2012			2011
Federal statutory rate		34	%		34	%		34	%
State tax, net of federal benefit		0.4	%		2.3	%		1.7	%
Effect of foreign taxes		(4.1	%)		(4.9	%)		(1.6	%)
Subpart F income		2.2	%		2.1	%		2.4	%
Valuation allowance		(38.2	%)		(6.6	%)		3.6	%
Foreign deferred tax liability offset		36.1	%		3.2	%		0	%
Manufacturing deduction		(2.9	%)		(3.5	%)		(0.7	%)
Research & development tax credits		(8.0	%)		0.6	%		0.7	%
Stock options		3.6	%		3.4	%		3	%
Uncertain tax positions		(5.1	%)		(0.4	%)		1.9	%
Italian permanent differences		5.2	%		4.9	%		0	%
Other permanent differences		3	%		4.1	%		1.4	%
Other		(0.2	%)		(3.8	%)		(3.5	%)
Effective tax rate		26	%		35.4	%		42.9	%
In March 2014, the German tax authority notified our German subsidiary that the tax years 2009 through 2012 would be audited. We expect the audit to commence during the third quarter of 2014. We believe there will be no material changes to its income tax liability as a result of this audit. We are not currently under audit in any other tax jurisdictions. As of December 31, 2013, a summary of the tax years that remain subject to examination in our most significant tax jurisdictions are:
United States		2010 and forward
Foreign		2007 and forward

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Stockholders' Equity	'
	10. Stockholders’ Equity
	Authorized Shares
	On June 14, 2012, our stockholders approved an amendment (Charter Amendment) to our Second Amended and Restated Certificate of Incorporation to reduce the number of authorized shares of common stock from 100,000,000 to 37,000,000 shares and of undesignated preferred stock from 5,000,000 to 3,000,000 shares. The Charter Amendment was previously approved by our Board of Directors on April 12, 2012, subject to approval by our stockholders. The Charter Amendment was filed with the Secretary of State of the State of Delaware on June 14, 2012.
	Stock Award Plans
	Under our 1997, 1998, 2000, and 2004 stock option plans, we authorized for the granting of options in the form of incentive stock options or non-qualified stock options to employees, directors, and consultants to purchase up to 1,688,702 shares of common stock. The stock options provide the holder the right to purchase common stock at a specific exercise price and the expected term will not exceed ten years. Incentive stock options are required to be issued at not less than fair market value at the date of the grant and generally vest over four or five years. The term of the options is determined by our Board of Directors but in no event will exceed ten years from date of grant, except with respect to one non-qualified option issued under our 1997 stock option plan.
	In May 2006 we approved a 2006 Stock Option and Incentive Plan (the 2006 Plan), which became effective upon the initial public offering. In 2010 we amended the 2006 Plan to increase the aggregate pool of available shares to 3,000,000 of common stock. The plan allows for granting of incentive stock options, non-qualified stock options, stock appreciation rights, RSUs, unrestricted stock awards, and deferred stock awards to our officers, employees, directors, and consultants. In connection with the adoption of the 2006 Plan, no further option grants are permitted under the 1997, 1998, 2000, and 2004 stock option plans and any expirations, cancellations, or terminations under the previous plans are available for issuance under the 2006 Plan. We may satisfy awards upon exercise of stock options or RSUs with either newly issued or treasury shares. The total number of shares currently authorized for stock award plans is 4,618,003 of which approximately 783,012 remain available for grant as of December 31, 2013.
	We have computed the fair value of employee stock options using the following weighted average assumptions:
			2013				2012				2011
	Dividend yield			1.8	%			1.6	%			1.1	%
	Volatility			57.8	%			61.8	%			66.1	%
	Risk-free interest rate			1.5	%			0.6	%			1.4	%
	Weighted average expected option term (in years)			5.5				5.5				4.8
	Weighted average fair value per share of options granted		$	3.01			$	2.91			$	3.57
	Aggregate intrinsic value of options exercised		$	1,009,726			$	340,678			$	321,584
	A summary of option activity as of December 31, 2013 and the year then ended is presented below:
			Number of				Weighted				Weighted			Aggregate
			Shares				Average				Average			Intrinsic
							Exercise				Remaining			Value
							Price				Contractual
											Term
											(in years)
	Balance outstanding at December 31, 2012			2,012,060			$	5.64				4.47		$	2,154,440
	Granted(1)			367,277			$	6.92
	Exercised(2)			(307,425	)		$	3.96						$	1,009,726
	Canceled / Expired			(209,112	)		$	8.84
	Balance outstanding at December 31, 2013(3)			1,862,800			$	5.81				4.82		$	4,815,870
	Vested and exercisable at December 31, 2013			1,002,215			$	5.7				4.82		$	3,482,730
	Expected to vest at December 31, 2013(4)			639,094			$	4.57				4.63
	Total			1,641,309
	-1	The aggregate intrinsic value represents the difference between the exercise price and the closing price of our stock on the day of grant.
	-2	The aggregate intrinsic value represents the difference between the exercise price and the closing price of our stock on the day of exercise.
	-3	The aggregate intrinsic value represents the difference between the exercise price and $8.01, the closing price of our stock on December 31, 2013, for all in-the-money options outstanding.
	-4	Options outstanding that are expected to vest are net of estimated future option forfeitures in accordance with the provisions set forth by the FASB.
	Restricted Stock Units
	A summary of our RSU activity, which is subject to fair value accounting requirements, is as follows:
			Shares				Weighted
							Average
							Grant
							Date Fair
							Value
	Balance outstanding at December 31, 2012			278,931			$	5.3
	Granted			117,873			$	6.67
	Vested(1)			(112,284	)		$	4.37
	Canceled			(30,223	)		$	6.04
	Balance outstanding at December 31, 2013			254,297			$	6.25
	-1	The number of RSUs vested includes the shares that we withheld on behalf of employees to satisfy minimum statutory tax withholding requirements.
	The fair values of the RSUs that vested during 2013, 2012, and 2011 were $0.8 million, $0.7 million, and $0.9 million, respectively.
	We repurchase shares of our common stock in order to cover any minimum tax withholding liability associated with RSU vestings. A summary of our repurchases is as follows:
			2013				2012
	Shares of common stock repurchased			41,259				42,991
	Per share repurchase price		$	6.9			$	6.11
	Aggregage purchase price		$	284,583			$	262,719
	Stock-based Compensation
	The components of stock-based compensation expense included in the consolidated statements of operations are as follows:
			2013				2012				2011
			(in thousands)
	Stock option awards to employees		$	789			$	692			$	591
	Restricted common stock awards			464				521				506
	Total stock-based compensation		$	1,253			$	1,213			$	1,097
	We expect to record the unamortized portion of share-based compensation expense of $2.6 million for existing stock options and RSUs outstanding at December 31, 2013, over a weighted-average period of 3.4 years.
	Stock Repurchase Plan
	In July 2009, our Board of Directors authorized a repurchase of our common stock from time to time on the open market or in privately negotiated transactions. In November 2011, our Board of Directors increased this authorization to $10.0 million and extended the program through December 31, 2013. The timing and number of any shares repurchased will be determined based on our evaluation of market conditions and other factors. Repurchases may also be made under a Rule 10b5-1 plan, which would permit shares to be repurchased when we might otherwise be precluded from doing so under insider trading laws. The repurchase program concluded as of December 31, 2013. The following is a summary of the stock repurchase activity for the year ended.
			December 31, 2013								December 31, 2012					December 31, 2011
		Shares				Total				Shares			Total		Shares		Total
		Purchased				Purchased				Purchased			Purchased		Purchased		Purchased
		( $ in thousands)
Share repurchases			15,323			$	88				304,846		$	1,759		300,326	$	1,904
Dividends
On February 24, 2011, our Board of Directors approved a policy for the payment of quarterly cash dividends on our common stock. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by our Board of Directors on a quarterly basis. The dividend activity for the periods presented is as follows:
Record Date		Payment Date		Per Share Amount				Dividend Payment
								(in thousands)
Fiscal Year 2013
March 20, 2013		3-Apr-13		$	0.03			$	457
May 22, 2013		5-Jun-13		$	0.03			$	457
August 21, 2013		4-Sep-13		$	0.03			$	460
November 20, 2013		4-Dec-13		$	0.03			$	464
Fiscal Year 2012
March 20, 2012		3-Apr-12		$	0.025			$	381
May 18, 2012		4-Jun-12		$	0.025			$	379
August 17, 2012		31-Aug-12		$	0.025			$	380
November 20, 2012		4-Dec-12		$	0.025			$	378
On February 20, 2014, our Board of Directors approved a quarterly cash dividend on our common stock of $0.035 per share payable on April 3, 2014, to stockholders of record at the close of business on March 20, 2014, which will total approximately $0.5 million.

ProfitSharing_Plan

Profit-Sharing Plan	12 Months Ended
	Dec. 31, 2013
Postemployment Benefits [Abstract]	'
Profit-Sharing Plan	'
	11. Profit-Sharing Plan
	We offer a 401(k) profit-sharing plan (the Plan) covering eligible U.S. employees to make tax deferred contributions, a portion of which are matched by us. We may make discretionary profit sharing contributions to the Plan in an amount determined by our Board of Directors. Our contributions vest ratably over six years of employment and amounted to approximately $40,000 for 2013 and were $0.1 million for 2011. Our 2012 contributions were funded from employee forfeitures.

Restructuring_Charges

Restructuring Charges	12 Months Ended
	Dec. 31, 2013
Restructuring And Related Activities [Abstract]	'
Restructuring Charges	'
	12. Restructuring Charges
	In October 2010, we adopted a reorganization plan (Biomateriali Plan) that was designed to eliminate redundant costs resulting from our 2007 acquisition of Biomateriali and to improve efficiencies in our manufacturing operations. In 2011, we incurred $0.3 million of charges associated with the transfer of manufacturing equipment to our Burlington factory and $0.7 million of non-cash charges related to the write-down of an asset for deferred rent, which was triggered by our exit of the Biomateriali facility in March 2011, and $0.1 million related to the repayment of grants and loans received from the Italian government associated with business incentive programs for the Biomateriali facility. We paid $0.4 million of severance related charges in 2011 and paid remaining $0.2 million in February 2012. We made the final payment to the Italian government of $0.5 million in December 2011. In March 2012, we completed the Biomateriali liquidation and dissolution process.
	In May 2011, we adopted a reorganization plan (LifeSpan Plan) that was designed to eliminate redundant costs resulting from our 2010 acquisition of the LifeSpan vascular graft and to improve efficiencies in our manufacturing operations. We transitioned the production of our LifeSpan vascular graft from Laguna Hills, California to our existing corporate headquarters in Burlington, Massachusetts. The LifeSpan Plan resulted in the termination of 7 employees at the Laguna Hills facility, relocation of manufacturing equipment, and the hiring of 4 employees to staff the required functions in Burlington. We incurred approximately $0.1 million related to the closure of the Laguna Hills facility and the related relocation of the manufacturing equipment during the year ended December 31, 2011. We incurred approximately $33,000 of severance charges related to this project during year ended December 31, 2011.
	On June 30, 2011, we terminated our relationship with our Spanish distributor resulting in a contract termination charge of $0.5 million which we recorded as restructuring charges (see Note 2 for further details regarding the transaction).
	On June 30, 2011, we terminated our relationship with our Danish distributor resulting in a contract termination charge of $0.1 million which we recorded as restructuring charges (see Note 2 for further details regarding the transaction).
	In July 2011, we adopted a reorganization plan of our European administrative and stent graft sales personnel as a result of our exit from our stent graft business. We terminated 6 employees and recorded severance charges of $0.3 million during the year ended December 31, 2011. The final severance payments were made in March 2012.
	The components of the restructuring charges are as follows:
		Year ended
		December 31, 2011
		(in thousands)
	Distributor termination charges	$	572
	Transfer of manufacturing equipment		446
	Employee severance costs		291
	Italian government loan and grant termination charge		79
	Non cash asset write-off		732
	Other		41
	Total	$	2,161
	Activity related to accrued restructuring costs is as follows:
		Year ended December 31,
		2012		2011
	Balance at beginning of year	$	101	$	922
	Plus:
	Current year restructuring costs		—		2,161
	Less:
	Payment for termination of contractual obligations		—		572
	Payment of employee severance costs		101		680
	Payment related to transfer manufacturing equipment		—		446
	Payment of Italian loan and grant		—		469
	Other		—		83
	Non-cash fixed asset write-off		—		732
	Balance at end of year	$	—	$	101
	In February 2014, we committed to a plan intended to improve operational efficiencies, which includes a reduction in force of approximately 10% of our workforce and other cost-cutting measures. The plan was implemented during the first quarter of 2014. We estimate that termination costs will be $0.2 million to $0.4 million. We expect to record the majority of these charges in 2014.

Segment_and_EnterpriseWide_Dis

Segment and Enterprise-Wide Disclosures	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment and Enterprise-Wide Disclosures	'
	13. Segment and Enterprise-wide Disclosures
	The FASB establishes standards for reporting information regarding operating segments in financial statements. Operating segments are identified as components of an enterprise about which separate, discrete financial information is available for evaluation by the chief operating decision-maker in making decisions on how to allocate resources and assess performance. We view our operations and manage our business as one operating segment. No discrete operating information is prepared by us except for product sales by product line and by legal entity for local reporting purposes.
	Most of our revenues were generated in the United States, Germany, Japan, Canada, and other European countries, and substantially all of our assets are located in the United States. Net sales to unaffiliated customers by country were as follows:
		Year ended December 31,
		2013		2012		2011
		(in thousands)
	United States	$	39,240	$	36,542	$	35,366
	Germany		6,939		5,647		7,276
	Japan		2,413		2,674		2,283
	Other countries		15,957		11,872		12,760
	Net sales	$	64,549	$	56,735	$	57,685
	Total property and equipment held by geography were as follows:
		As of December 31,
		2013		2012
		(in thousands)
	United States	$	5,391	$	4,162
	Germany		229		232
	Other countries		190		150
	Total property and equipment	$	5,810	$	4,544

Supplemental_Cash_Flow_Informa

Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2013
Supplemental Cash Flow Elements [Abstract]	'
Supplemental Cash Flow Information	'
	14. Supplemental Cash Flow Information
	Supplemental disclosures of cash flow information are as follows:
		Year ended December 31,
		2013		2012		2011
		(in thousands)
	Cash paid for income taxes, net	$	1,019	$	544	$	717

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	15. Fair Value Measurements
	The fair value accounting guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:
		•		Level 1—Quoted prices in active markets for identical assets or liabilities.
		•		Level 2—Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
		•		Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.
	As of December 31, 2013, we had cash equivalents in a money market fund that was valued using Level 1 inputs (quoted market prices for identical assets) at a fair value of $8.3 million.
	We had no Level 2 assets being measured at fair value on a recurring basis as of December 31, 2013.
	As discussed in Notes 1and 2, several measurements of acquisition-related assets and impairments of intangible assets were measured using Level 3 techniques. The following table provides a rollforward of the fair value, as determined by Level 3 inputs, of the contingent consideration.
			Year ended
			December 31,  2013
			(in thousands)
	Beginning balance		$	—
	Additions			42
	Payments			—
	Change in fair value included in earnings			57
	Ending balance		$	99

Quarterly_Financial_Data_Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Data (Unaudited)	'
	16. Quarterly Financial Data (unaudited)
			Three months ended
	2013		March 31		June 30 (1)		September 30		December 31
			(in thousands, except per share data)
	Total net sales		$	15,382	$	15,951	$	15,300	$	17,916
	Gross profit			11,206		11,237		10,716		11,956
	Income from operations			1,123		1,447		776		1,172
	Net income			846		889		721		746
	Earnings per share
	Basic		$	0.06	$	0.06	$	0.05	$	0.05
	Diluted		$	0.05	$	0.06	$	0.05	$	0.05
			Three months ended
	2012		March 31		June 30		September 30		December 31
			(in thousands, except per share data)
	Total net sales		$	13,928	$	14,361	$	13,645	$	14,801
	Gross profit			9,870		10,545		10,015		10,438
	Income from operations			854		1,455		1,001		930
	Net income			386		824		663		698
	Earnings per share
	Basic		$	0.03	$	0.05	$	0.04	$	0.05
	Diluted		$	0.02	$	0.05	$	0.04	$	0.04
	-1	During the second quarter of 2013, we identified an error in our historic inventory valuation that resulted in an understatement of the periodic carrying amount of our inventory. We corrected this error which resulted in an understatement of cost of sales of $0.4 million and an overstatement of net income of $0.3 million in the three months ended June 30, 2013.

Significant_Accounting_Policie1

Significant Accounting Policies and Related Matters (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Description of Business	'
	Description of Business
	Unless the context requires otherwise, references to LeMaitre Vascular, we, our, and us refer to LeMaitre Vascular, Inc. and our subsidiaries. We develop, manufacture, and market medical devices and implants used primarily in the field of vascular surgery. We operate in a single segment in which our principal product lines include the following: valvulotomes, balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. Our offices are located in Burlington, Massachusetts; Mississauga, Canada; Sulzbach, Germany; Milan, Italy; Madrid, Spain; Melbourne, Australia and Tokyo, Japan.
Consolidation and Basis of Presentation	'
	Consolidation and Basis of Presentation
	Our consolidated financial statements include the accounts of LeMaitre Vascular and the accounts of our wholly-owned subsidiaries, LeMaitre Vascular GmbH, LeMaitre Vascular GK, Vascutech Acquisition LLC, LeMaitre Acquisition LLC, LeMaitre Vascular SAS, LeMaitre Vascular S.r.l., LeMaitre Vascular Spain SL, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LeMaitre Vascular AS, and LeMaitre Vascular Pty Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation.
Foreign Currency Translation	'
	Foreign Currency Translation
	Balance sheet accounts of foreign subsidiaries are translated into U.S. dollars at year-end exchange rates. Operating accounts are translated at average exchange rates for each year. Net translation gains or losses are adjusted directly to a separate component of other comprehensive income (loss) within stockholders’ equity. Foreign exchange transaction gains (losses), substantially all of which relate to intercompany activity between us and our foreign subsidiaries, are included in other income (expense) in the accompanying consolidated statements of operations.
Estimates	'
	Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to bad debts, inventories, intangible assets, sales returns and discounts, and income taxes are reviewed on an ongoing basis and updated as appropriate. Actual results could differ from those estimates.
Revenue Recognition	'
	Revenue Recognition
	Our revenue is derived primarily from the sale of disposable or implantable devices used during vascular surgery. We sell primarily directly to hospitals and to a lesser extent to distributors, as described below, and, during the periods presented in our consolidated financial statements, entered into consigned inventory arrangements with either hospitals or distributors on a limited basis.
	We recognize revenue when four basic criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. We assess whether the fee is fixed or determinable based on the terms of the agreement associated with the transaction. Sales transactions are based on prices that are determinable at the time the customer’s purchase order is accepted by us. Orders that are not accompanied with a purchase order are either confirmed in writing or verbally with the customer.
	After the delivery of the product, there is no uncertainty about customer acceptance due to the nature of the product. There is no contingency for acceptance, warranty, or price protection. We do not recognize revenue on consigned sales until the customer notifies us that the products have been used. In order to determine whether collection is reasonably assured, we assess a number of factors, including past transaction history with the customer and the creditworthiness of the customer. If we determine that collection is not reasonably assured, we defer the recognition of revenue until collection becomes reasonably assured, which is generally upon receipt of payment. We provide for product returns at the time revenue is recognized based on our product return history.
	Based on these policies, we recognize revenue, net of allowances for returns and discounts, as products are shipped, based on shipping point terms, or at the time consigned inventory is consumed at which time title passes to customers. We recognize revenue net of allowances for returns and discounts, at the time of shipment of our products to our distributors. Customers returning products are entitled to full or partial credit based on the condition and timing of the return. To be accepted, a returned product must be unopened (if sterile), unadulterated, and undamaged, must have at least 18 months remaining prior to its expiration date, or twelve months for our hospital customers in Europe, and generally be returned within 30 days of shipment. These return policies apply to sales to both hospitals and distributors. The amount of products returned to us, either for exchange or credit, has not been material. Nevertheless, we provide for an allowance for future sales returns based on historical return experience. Our cost of replacing defective products has not been material and is accounted for at the time of replacement.
Research and Development Expense	'
	Research and Development Expense
	Research and development costs, principally salaries, laboratory testing, and supplies, are expensed as incurred and also include royalty payments associated with licensed and acquired intellectual property.
Shipping and Handling Costs	'
	Shipping and Handling Costs
	Shipping and handling fees paid by customers are recorded within net sales, with the related expense recorded in cost of sales.
Advertising Costs	'
	Advertising Costs
	Advertising costs are expensed as incurred and are included as a component of sales and marketing expense in the accompanying consolidated statements of operations. Advertising costs are as follows:
		Year ended December 31,
		2013		2012		2011
				(in thousands)
	Advertising expense	$	421	$	717	$	410
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	We consider all highly liquid instruments purchased with maturity dates of 90 days or less to be cash equivalents. Cash and cash equivalents are primarily invested in money market funds. These amounts are stated at cost, which approximates fair value.
Concentrations of Credit Risk	'
	Concentrations of Credit Risk
	Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, accounts receivable, and notes receivable. Cash equivalents represent highly liquid investments with maturities of 90 days or less at the date of purchase. Marketable securities are investment grade, interest-earning securities and are diversified by type and industry. Credit risk related to cash, cash equivalents, and marketable securities are limited based on the creditworthiness of the financial institutions at which these funds are held. Credit risk related to notes receivable is assessed based upon the individual payor as of the original fair value determination and updated periodically as required.
	Our accounts receivable are with customers based in the United States and internationally. Accounts receivable generally are due within 30 to 90 days of invoice and are stated at amounts due from customers, net of an allowance for doubtful accounts and sales returns, other than in certain European markets where longer payment terms are customary and may range from 90 to 240 days. We perform ongoing credit evaluations of the financial condition of our customers and adjust credit limits based upon payment history and the current creditworthiness of the customers, as determined by a review of their current credit information. We continuously monitor aging reports, collections, and payments from customers, and maintain a provision for estimated credit losses based upon historical experience and any specific customer collection issues we identify.
	We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our European sales to government-owned or supported customers such as hospitals, distributors and agents, in Southern Europe, specifically Italy and Spain may be subject to significant payment delays due to government austerity measures impacting funding and payment practices. As of December 31, 2013 our receivables in Italy and Spain totaled $1.2 million and $0.5 million, respectively. Receivables balances with certain publicly-owned hospitals and government supported customers in these countries can accumulate over a period of time and then subsequently be settled as large lump sum payments. While we believe our allowance for doubtful accounts in these countries is adequate as of December 31, 2013, if significant changes were to occur in the payment practices of these European governments or if government funding becomes unavailable, we may not be able to collect on receivables due to us from these customers and our write offs of uncollectible amounts may increase.
	We write off accounts receivable when they become uncollectible. Such credit losses have historically been within our expectations and allowances. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable. We review our allowance for doubtful accounts on a monthly basis and all past due balances are reviewed individually for collectability. The provision for the allowance for doubtful accounts is recorded in general and administrative expenses. The following is a summary of our allowance for doubtful accounts and sales returns:
		Balance at		Additions		Deductions		Balance
		Beginning		Charged to		from		at End of
		of Period		Income		Reserves		Period
		(in thousands)
	Allowance for doubtful accounts and sales returns:
	Year ended December 31, 2013	$	326	$	29	$	92	$	263
	Year ended December 31, 2012		211		153		38		326
	Year ended December 31, 2011		184		56		29		211
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	Our financial instruments include cash and cash equivalents, marketable securities, accounts receivable, trade payables, and notes payable. The fair value of the majority of these instruments approximates their carrying value based upon their short-term nature or variable rates of interest.
Inventory	'
	Inventory
	Inventory consists of finished products, work-in-process, and raw materials. We value inventory at the lower of cost or market value. Cost includes materials, labor, and manufacturing overhead and is determined using the first-in, first-out (FIFO) method. On a quarterly basis, we review inventory quantities on hand and analyze the provision for excess and obsolete inventory based primarily on product expiration dating and our estimated sales forecast, which is based on sales history and anticipated future demand. Our estimates of future product demand may not be accurate, and we may understate or overstate the provision required for excess and obsolete inventory. Accordingly, any significant unanticipated changes in demand could have a significant impact on the value of our inventory and results of operations.
Property and Equipment	'
	Property and Equipment
	Property and equipment are recorded at cost. Depreciation is provided over the estimated useful lives of the related assets using straight-line method as follows:
	Description	Useful Life
	Computers and equipment	3–5 years
	Machinery and equipment	3–10 years
	Leasehold improvements	The shorter of its useful life or lease term
	Expenditures for maintenance and repairs are charged to operations when incurred, while additions and betterments are capitalized. When assets are retired or disposed, the asset’s original cost and related accumulated depreciation are eliminated from the accounts and any gain or loss is reflected in the statement of operations.
Valuation of Business Combinations	'
	Valuation of Business Combinations
	We assign the value of the consideration transferred to acquire a business to the tangible assets and identifiable intangible assets acquired and liabilities assumed on the basis of their fair values at the date of acquisition. We assess the fair value of assets, including intangible assets, using a variety of methods and are usually performed by an independent appraiser who measures fair value from the perspective of a market participant.
	Acquisitions have been accounted for using the acquisition method, and the acquired companies’ results have been included in the accompanying consolidated financial statements from their respective dates of acquisition. Acquisition transaction costs have been recorded in general and administrative expenses, and are expensed as incurred. Allocation of the purchase price for acquisitions is based on estimates of the fair value of the net assets acquired and, for acquisitions completed within the past year, is subject to adjustment upon finalization of the purchase price allocation.
	Our acquisitions have historically been made at prices above the fair value of the acquired assets, resulting in goodwill, due to expectations of synergies of combining the businesses. These synergies include use of our existing commercial infrastructure to expand sales of the acquired businesses’ products, use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of our products, and the elimination of redundant facilities, functions and staffing.
Contingent Consideration	'
	Contingent Consideration
	The Financial Accounting Standards Board (the FASB) requires contingent consideration be recognized at the date of acquisition, based on the fair value at that date, and then re-measured periodically through adjustments to net income.
Impairment of Long-Lived Assets	'
	Impairment of Long-lived Assets
	We review our long-lived assets (primarily property and equipment and intangible assets) subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall, or an adverse action or assessment by a regulator. If an impairment indicator exists, we test the intangible asset for recoverability. We record impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. Impairment is measured based on the fair market value of the affected asset using discounted cash flows.
	In 2011, we determined that certain patents within our portfolio in the United States and Europe had no value based upon an analysis of expected economic benefits. As a result, we recorded an impairment charge of $0.1 million for the write-down of these patents.
	This impairment adjustment falls within Level 3 of the fair value hierarchy, due to the use of significant unobservable inputs to determine fair value. The fair value measurements were calculated using unobservable inputs, primarily using the income approach, specifically the discounted cash flow method. The amount and timing of future cash flows within our analysis was based on our most recent operational budgets, long range strategic plans and other estimates.
Goodwill	'
	Goodwill
	Goodwill represents the amount of consideration paid in connection with business acquisitions in excess of the fair value of assets acquired and liabilities assumed. Goodwill is evaluated for impairment annually or more frequently if indicators of impairment are present or changes in circumstances suggest that an impairment may exist. We evaluate the December 31 balance of the carrying value of goodwill based on a single reporting unit annually. We perform an assessment of qualitative factors to determine if it is “more likely than not” that the fair value of our reporting unit is less than its carrying value as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. The “more likely than not” threshold is defined as having a likelihood of more than 50 percent. If required, the next step of the goodwill impairment test is to determine the fair value of the reporting unit. The implied fair value of goodwill is determined on the same basis as the amount of goodwill recognized in connection with a business combination. Specifically, the fair value of a reporting unit is allocated to all of the assets and liabilities (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination as of the date of the impairment review and as if the fair value of the reporting unit was the price paid to acquire the reporting unit. The excess of the fair value of a reporting unit over the amounts assigned to its assets and liabilities is the implied fair value of goodwill. If the carrying amount of the reporting unit goodwill exceeds the implied fair value of that goodwill, an impairment loss shall be recognized in an amount equal to that excess. We have determined that no goodwill impairment charges were required for the years ended December 31, 2013, 2012, or 2011.
Other Intangible Assets	'
	Other Intangible Assets
	Other intangible assets consist primarily of patents, trademarks, technology licenses, and customer relationships acquired in connection with business acquisitions and asset acquisitions and are amortized over their estimated useful lives, ranging from 1 to 13 years.
Stock-Based Compensation	'
	Stock-based Compensation
	We recognize, as expense, the estimated fair value of stock options to employees which is determined using the Black-Scholes option pricing model. We have elected to recognize the compensation cost of all share-based awards on a straight-line basis over the vesting period of the award. In periods that we grant stock options, fair value assumptions are based on volatility, interest, dividend yield, and expected term over which the stock options will be outstanding. The computation of expected volatility is based on the historical volatility of the company’s stock. The interest rate for periods within the contractual life of the award is based on the U.S. Treasury risk-free interest rate in effect at the time of grant. Historical data on exercise patterns is the basis for estimating the expected life of an option. The expected annual dividend rate was calculated by dividing our annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date.
	We also issue restricted stock units (RSUs) as an additional form of equity compensation to our employees, officers, and directors, pursuant to our stockholder-approved 2006 Plan. RSUs entitle the grantee to an issuance of stock at no cost and generally vest over a period of time determined by our Board of Directors at the time of grant based upon the continued service to the company. The fair market value of the award is determined based on the number of RSUs granted and the market value of our common stock on the grant date and is amortized to expense over the period of vesting. Unvested RSUs are forfeited and canceled as of the date that employment or service to the company terminates. RSUs are settled in shares of our common stock upon vesting. We may repurchase common stock upon our employees’ vesting in RSUs in order to cover any minimum tax withholding liability as a result of the RSUs having vested.
	Share-based compensation charges are recorded net of the estimated forfeitures based upon historical rates and will be adjusted in future periods to reflect the results of actual forfeitures and vesting. Share-based compensation charges are recorded across the consolidated statement of operations based upon the grantee’s primary function.
Commitments and Contingencies	'
	Commitments and Contingencies
	In the normal course of business, we are subject to proceedings, lawsuits, and other claims and assessments for matters related to, among other things, patent infringement, business acquisitions, employment, and product recalls. We assess the likelihood of any adverse judgments or outcomes to these matters as well as potential ranges of probable losses. A determination of the amount of reserves required, if any, for these contingencies is made after careful analysis of each individual issue. The required reserves may change in the future due to new developments in each matter or changes in approach such as a change in settlement strategy in dealing with these matters. We record charges for the losses we anticipate incurring in connection with litigation and claims against us when we conclude a loss is probable and we can reasonably estimate these losses. During the years ended December 31, 2013, 2012, and 2011, we were not subject to any material litigation or claims and assessments.
Income Taxes	'
	Income Taxes
	We account for income taxes under the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred taxes are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The provision for income taxes includes taxes currently payable and deferred taxes resulting from the tax effects of temporary differences between the financial statement and tax bases of assets and liabilities. We maintain valuation allowances where it is more likely than not that all or a portion of a deferred tax asset will not be realized. Changes in the valuation allowances are included in our tax provision in the period of change. In determining whether a valuation allowance is warranted, we evaluate factors such as prior earnings history, expected future earnings, carry-back and carry-forward periods and tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset.
	We recognize, measure, present and disclose in our financial statements, uncertain tax positions that we have taken or expect to take on a tax return. We recognize in our financial statements the impact of tax positions that meet a “more likely than not” threshold, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement.
	Our policy is to classify interest and penalties related to unrecognized tax benefits as income tax expense.
Comprehensive Income	'
	Comprehensive Income
	Comprehensive income is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other than reported net income, comprehensive income includes foreign currency translation adjustments, which are disclosed in the accompanying consolidated statements of comprehensive income. There were no reclassifications out of comprehensive income for the years ended December 31, 2013 and 2012.
	Accumulated other comprehensive loss consisted of foreign currency translation adjustment losses of $0.3 million and $0.4 million as of December 31, 2013 and 2012, respectively.
Restructuring	'
	Restructuring
	We record restructuring charges incurred in connection with consolidation or relocation of operations, exited business lines, reductions in force, or distributor terminations. These restructuring charges, which reflect our commitment to a termination or exit plan that will begin within twelve months, are based on estimates of the expected costs associated with site closure, legal matters, contract terminations, severance payments, or other costs directly related to the restructuring. If the actual cost incurred exceeds the estimated cost, an additional charge to earnings will result. If the actual cost is less than the estimated cost, a credit to earnings will be recognized.
Earnings Per Share	'
	Earnings per Share
	We compute basic earnings per share by dividing net income available for common stockholders by the weighted average number of shares outstanding during the year. Except where the result would be anti-dilutive to net income per share, diluted earnings per share has been computed using the treasury stock method and reflects the potential vesting of restricted common stock and the potential exercise of stock options, as well as their related income tax effects.
	The computation of basic and diluted net income per share is as follows:
		Year ended December 31,
		2013		2012		2011
		(in thousands, except per share data)
	Basic:
	Net income available for common stockholders	$	3,202	$	2,571	$	2,143
	Weighted average shares outstanding		15,317		15,194		15,458
	Basic earnings per share	$	0.21	$	0.17	$	0.14
	Diluted:
	Net income available for common stockholders	$	3,202	$	2,571	$	2,143
	Weighted-average shares outstanding		15,317		15,194		15,458
	Common stock equivalents, if dilutive		447		444		531
	Shares used in computing diluted earnings per common share		15,764		15,638		15,989
	Diluted earnings per share	$	0.2	$	0.16	$	0.13
	Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive		373		549		355
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In February 2013, the FASB issued new guidance which requires disclosure of changes in accumulated other comprehensive income balances by component and significant reclassification adjustments from accumulated other comprehensive income in a single note or on the face of the financial statements. This guidance became effective January 1, 2013. The adoption of this standard, which is related to disclosure only, did not have an impact on our results of operations or financial position.
	In July 2013, the FASB issued guidance to address the diversity in practice related to the financial statement presentation of unrecognized tax benefits as either a reduction of a deferred tax asset or a liability when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of this guidance is not expected to have a material impact on our consolidated financial statements.

Significant_Accounting_Policie2

Significant Accounting Policies and Related Matters (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Advertising Costs	'
	Advertising costs are as follows:
		Year ended December 31,
		2013		2012		2011
				(in thousands)
	Advertising expense	$	421	$	717	$	410
Summary of Allowance for Doubtful Accounts and Sales Returns	'
	The following is a summary of our allowance for doubtful accounts and sales returns:
		Balance at		Additions		Deductions		Balance
		Beginning		Charged to		from		at End of
		of Period		Income		Reserves		Period
		(in thousands)
	Allowance for doubtful accounts and sales returns:
	Year ended December 31, 2013	$	326	$	29	$	92	$	263
	Year ended December 31, 2012		211		153		38		326
	Year ended December 31, 2011		184		56		29		211
Summary of Property and Equipment	'
	Property and equipment are recorded at cost. Depreciation is provided over the estimated useful lives of the related assets using straight-line method as follows:
	Description	Useful Life
	Computers and equipment	3–5 years
	Machinery and equipment	3–10 years
	Leasehold improvements	The shorter of its useful life or lease term
Computation of Basic and Diluted Net Income Per Share	'
	The computation of basic and diluted net income per share is as follows:
		Year ended December 31,
		2013		2012		2011
		(in thousands, except per share data)
	Basic:
	Net income available for common stockholders	$	3,202	$	2,571	$	2,143
	Weighted average shares outstanding		15,317		15,194		15,458
	Basic earnings per share	$	0.21	$	0.17	$	0.14
	Diluted:
	Net income available for common stockholders	$	3,202	$	2,571	$	2,143
	Weighted-average shares outstanding		15,317		15,194		15,458
	Common stock equivalents, if dilutive		447		444		531
	Shares used in computing diluted earnings per common share		15,764		15,638		15,989
	Diluted earnings per share	$	0.2	$	0.16	$	0.13
	Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive		373		549		355

Acquisitions_and_Divestitures_

Acquisitions and Divestitures (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	'
	The following table summarizes the final purchase accounting for the fair value of the assets acquired and liabilities assumed at the date of the acquisition:
		Allocated
		Fair Value
		(in thousands)
	Current Assets	$	12
	Intangible assets		2,756
	Goodwill		1,832
	Total assets acquired		4,600
	Total liabilities assumed		—
		$	4,600
Acquired Intangible Assets and Related Estimated Useful Lives	'
	the following table reflects the allocation of the acquired intangible assets and related estimated useful lives:
		Allocated			Weighted
		Fair Value			Average
					Useful Life
		(in thousands)
	Patents	$	2,450			13.0 years
	Non-compete agreement		306			5.0 years
	Total intangible assets	$	2,756
Clinical Instruments [Member]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	'
	The following table summarizes the fair value of the assets acquired and liabilities assumed at the date of the acquisition:
		Allocated
		Fair Value
		(in thousands)
	Current assets	$	169
	Intangible assets		322
	Goodwill		614
	Total assets acquired		1,105
	Total liabilities assumed		—
		$	1,105
Acquired Intangible Assets and Related Estimated Useful Lives	'
	the following table reflects the allocation of the acquired intangible assets and related estimated useful lives:
		Allocated			Weighted
		Fair Value			Average
					Useful Life
		(in thousands)
	Non-compete agreement	$	95			5.0 years
	Technology	$	147			6.0 years
	Customer relationships		80			6.0 years
	Total intangible assets	$	322
InaVein LLC [Member]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	'
	The following table summarizes the fair value of the assets acquired and liabilities assumed at the date of the acquisition:
		Allocated
		Fair Value
		(in thousands)
	Current assets	$	670
	Property and equipment, net		154
	Intangible assets		1,143
	Goodwill		668
	Total assets acquired		2,635
	Total liabilities assumed		(100	)
		$	2,535
Acquired Intangible Assets and Related Estimated Useful Lives	'
	the following table reflects the allocation of the acquired intangible assets and related estimated useful lives:
		Allocated			Weighted
		Fair Value			Average
					Useful Life
		(in thousands)
	Non-compete agreement	$	70			5.0 years
	Tradename		163			8.0 years
	Technology		354			6.0 years
	Customer relationships		556			7.0 years
	Total intangible assets	$	1,143

Inventory_Tables

Inventory (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Summary of Inventory	'
	Inventory consists of the following:
		As of December 31,
		2013		2012
		(in thousands)
	Raw materials	$	3,647	$	2,471
	Work-in-process		2,949		2,084
	Finished products		6,659		6,304
	Total inventory	$	13,255	$	10,859

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Summary of Property and Equipment	'
	Property and equipment consists of the following:
		As of December 31,
		2013			2012
		(in thousands)
	Computers and equipment	$	2,369		$	2,196
	Machinery and equipment		6,570			5,599
	Leasehold improvements		4,104			2,968
	Gross property and equipment		13,043			10,763
	Less accumulated depreciation		(7,233	)		(6,219	)
	Property and equipment, net	$	5,810		$	4,544
Depreciation Expense	'
	Depreciation expense is as follows:
		Year ended December 31,
		2013			2012			2011
					(in thousands)
	Depreciation expense	$	1,573		$	1,319		$	1,047

Goodwill_and_Other_Intangibles1

Goodwill and Other Intangibles (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill	'
	Goodwill consists of the following:
		As of December 31,
		2013		2012
		(in thousands)
	Balance at beginning of year	$	13,749	$	11,917
	Additions for acquisitions		1,282		1,832
	Balance at end of year	$	15,031	$	13,749
Components of Other Intangibles	'
	Other intangibles consist of the following:
		2013						2012
		Gross		Accumulated		Net		Gross		Accumulated		Net
		Carrying		Amortization		Carrying		Carrying		Amortization		Carrying
		Value				Value of		Value				Value of
						Intangible						Intangible
						Assets						Assets
		(in thousands)
	Patents	$	5,679	$	1,932	$	3,747	$	5,108	$	1,339	$	3,769
	Trademarks and technology licenses		1,414		935		479		1,157		821		336
	Customer relationships		2,835		1,441		1,394		1,757		1,001		756
	Other intangible assets		971		447		524		673		343		330
	Total identifiable intangible assets	$	10,899	$	4,755	$	6,144	$	8,695	$	3,504	$	5,191
Amortization Expense Included in General and Administrative Expense	'
	Amortization expense is included in general and administrative expense and is as follows:
		Year ended December 31,
		2013		2012		2011
		(in thousands)
	Amortization expense	$	1,220	$	915	$	990
Estimated Amortization Expense for Each of Five Succeeding Fiscal Years	'
	Estimated amortization expense for each of the five succeeding fiscal years, based upon the intangible assets at December 31, 2013, is as follows:
		Year ended December 31,
		2014		2015		2016		2017		2018
			(in thousands)
	Amortization expense	$	1,414	$	1,015	$	870	$	612	$	497

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Accrued Expenses	'
	Accrued expenses consist of the following:
		As of December 31,
		2013		2012
		(in thousands)
	Compensation and related taxes	$	4,710	$	3,860
	Income and other taxes		885		963
	Professional fees		428		521
	Other		1,970		1,433
	Total	$	7,993	$	6,777

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Summary of Rent Expenses	'
	Rent expense was as follows:
		Year ended December 31,
		2013		2012		2011
		(in thousands)
	Rent expense	$	1,264	$	1,030	$	1,182
Minimum Rental Commitments Under All Non-Cancelable Operating Leases With Initial or Remaining Terms of More Than One Year	'
	At December 31, 2013, the minimum rental commitments under all non-cancelable operating leases with initial or remaining terms of more than one year, for each of the following fiscal years, are as follows:
		Year ended December 31,
		2014		2015		2016		2017		2018		Thereafter
		(in thousands)
	Operating leases	$	1,159	$	1,119	$	914	$	689	$	802	$	4,075

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income (Loss) Before Income Taxes	'
	Income (loss) before income taxes is as follows:
		Year ended December 31,
		2013			2012			2011
		(in thousands)
	United States	$	4,692		$	3,918		$	3,511
	Foreign		(364	)		75			241
	Total	$	4,328		$	3,993		$	3,752
The Provision (Benefit) for Income Taxes	'
	The provision (benefit) for income taxes is as follows:
		Year ended December 31,
		2013			2012			2011
		(in thousands)
	Current:
	Federal	$	504		$	881		$	309
	State		143			100			9
	Foreign		192			154			132
			839			1,135			450
	Deferred:
	Federal		1,968			503			831
	State		(84	)		12			116
	Foreign		(1,597	)		(228	)		212
			287			287			1,159
	Provision for income taxes	$	1,126		$	1,422		$	1,609
Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits	'
	A reconciliation of beginning and ending amount of our unrecognized tax benefits is as follows:
		2013			2012			2011
		(in thousands)
	Unrecognized tax benefits at the beginning of year	$	321		$	329		$	277
	Additions for tax positions of current year		—			—			52
	Additions for tax positions of prior years		—			6			—
	Reductions for lapses of the applicable statutes of limitations		(210	)		(14	)		—
	Unrecognized tax benefits at the end of the year	$	111		$	321		$	329
Deferred Taxes	'
	Deferred taxes are attributable to the following temporary differences:
		As of December 31,
		2013			2012
		(in thousands)
	Deferred tax assets:
	Inventory	$	824		$	772
	Net operating loss carryforwards		2,190			2,561
	Tax credit carryforwards		551			555
	Reserves and accruals		313			263
	Intangible assets		1,102			916
	Stock options		203			326
	Other		38			288
	Total deferred tax assets		5,221			5,681
	Deferred tax liabilities:
	Property and equipment		(742	)		(692	)
	Goodwill		(2,727	)		(2,374	)
	Foreign branch deferred offset		(1,735	)		(146	)
	Other		—			(26	)
	Total deferred tax liabilities		(5,204	)		(3,238	)
	Net deferred tax assets before valuation allowance		17			2,443
	Valuation allowance		(969	)		(3,053	)
	Net deferred tax liabiltity	$	(952	)	$	(610	)
	Deferred tax classification
	Short-term deferred tax asset	$	932		$	850
	Short-term deferred tax liability		(38	)		(60	)
	Net short-term deferred tax asset	$	894		$	790
	Long-term deferred tax asset	$	1,615		$	273
	Long-term deferred tax liability		(3,461	)		(1,673	)
	Net long-term deferred tax liability	$	(1,846	)	$	(1,400	)
	Net deferred tax liability	$	(952	)	$	(610	)
Reconciliation of the Federal Statutory Rate to Effective Tax Rate	'
	A reconciliation of the Federal statutory rate to our effective tax rate is as follows:
		2013			2012			2011
	Federal statutory rate		34	%		34	%		34	%
	State tax, net of federal benefit		0.4	%		2.3	%		1.7	%
	Effect of foreign taxes		(4.1	%)		(4.9	%)		(1.6	%)
	Subpart F income		2.2	%		2.1	%		2.4	%
	Valuation allowance		(38.2	%)		(6.6	%)		3.6	%
	Foreign deferred tax liability offset		36.1	%		3.2	%		0	%
	Manufacturing deduction		(2.9	%)		(3.5	%)		(0.7	%)
	Research & development tax credits		(8.0	%)		0.6	%		0.7	%
	Stock options		3.6	%		3.4	%		3	%
	Uncertain tax positions		(5.1	%)		(0.4	%)		1.9	%
	Italian permanent differences		5.2	%		4.9	%		0	%
	Other permanent differences		3	%		4.1	%		1.4	%
	Other		(0.2	%)		(3.8	%)		(3.5	%)
	Effective tax rate		26	%		35.4	%		42.9	%
Summary of Tax Years Subject to Examination in Most Significant Tax Jurisdictions	'
	As of December 31, 2013, a summary of the tax years that remain subject to examination in our most significant tax jurisdictions are:
	United States		2010 and forward
	Foreign		2007 and forward

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Fair Value of Employee Stock Options Using Weighted Average Assumptions	'
	We have computed the fair value of employee stock options using the following weighted average assumptions:
			2013				2012				2011
	Dividend yield			1.8	%			1.6	%			1.1	%
	Volatility			57.8	%			61.8	%			66.1	%
	Risk-free interest rate			1.5	%			0.6	%			1.4	%
	Weighted average expected option term (in years)			5.5				5.5				4.8
	Weighted average fair value per share of options granted		$	3.01			$	2.91			$	3.57
	Aggregate intrinsic value of options exercised		$	1,009,726			$	340,678			$	321,584
Summary of Option Activity	'
	A summary of option activity as of December 31, 2013 and the year then ended is presented below:
			Number of				Weighted				Weighted			Aggregate
			Shares				Average				Average			Intrinsic
							Exercise				Remaining			Value
							Price				Contractual
											Term
											(in years)
	Balance outstanding at December 31, 2012			2,012,060			$	5.64				4.47		$	2,154,440
	Granted(1)			367,277			$	6.92
	Exercised(2)			(307,425	)		$	3.96						$	1,009,726
	Canceled / Expired			(209,112	)		$	8.84
	Balance outstanding at December 31, 2013(3)			1,862,800			$	5.81				4.82		$	4,815,870
	Vested and exercisable at December 31, 2013			1,002,215			$	5.7				4.82		$	3,482,730
	Expected to vest at December 31, 2013(4)			639,094			$	4.57				4.63
	Total			1,641,309
	-1	The aggregate intrinsic value represents the difference between the exercise price and the closing price of our stock on the day of grant.
	-2	The aggregate intrinsic value represents the difference between the exercise price and the closing price of our stock on the day of exercise.
	-3	The aggregate intrinsic value represents the difference between the exercise price and $8.01, the closing price of our stock on December 31, 2013, for all in-the-money options outstanding.
	-4	Options outstanding that are expected to vest are net of estimated future option forfeitures in accordance with the provisions set forth by the FASB.
Summary of RSU Activity	'
	A summary of our RSU activity, which is subject to fair value accounting requirements, is as follows:
			Shares				Weighted
							Average
							Grant
							Date Fair
							Value
	Balance outstanding at December 31, 2012			278,931			$	5.3
	Granted			117,873			$	6.67
	Vested(1)			(112,284	)		$	4.37
	Canceled			(30,223	)		$	6.04
	Balance outstanding at December 31, 2013			254,297			$	6.25
	-1	The number of RSUs vested includes the shares that we withheld on behalf of employees to satisfy minimum statutory tax withholding requirements.
Summary of Repurchases	'
	A summary of our repurchases is as follows:
			2013				2012
	Shares of common stock repurchased			41,259				42,991
	Per share repurchase price		$	6.9			$	6.11
	Aggregage purchase price		$	284,583			$	262,719
Share-Based Compensation Expense	'
	The components of stock-based compensation expense included in the consolidated statements of operations are as follows:
			2013				2012				2011
			(in thousands)
	Stock option awards to employees		$	789			$	692			$	591
	Restricted common stock awards			464				521				506
	Total stock-based compensation		$	1,253			$	1,213			$	1,097
Stock Repurchase Activity	'
	The following is a summary of the stock repurchase activity for the year ended.
			December 31, 2013								December 31, 2012					December 31, 2011
			Shares				Total				Shares			Total		Shares		Total
			Purchased				Purchased				Purchased			Purchased		Purchased		Purchased
			( $ in thousands)
	Share repurchases			15,323			$	88				304,846		$	1,759		300,326	$	1,904
Dividend Activity	'
	The dividend activity for the periods presented is as follows:
	Record Date		Payment Date		Per Share Amount				Dividend Payment
									(in thousands)
	Fiscal Year 2013
	March 20, 2013		3-Apr-13		$	0.03			$	457
	May 22, 2013		5-Jun-13		$	0.03			$	457
	August 21, 2013		4-Sep-13		$	0.03			$	460
	November 20, 2013		4-Dec-13		$	0.03			$	464
	Fiscal Year 2012
	March 20, 2012		3-Apr-12		$	0.025			$	381
	May 18, 2012		4-Jun-12		$	0.025			$	379
	August 17, 2012		31-Aug-12		$	0.025			$	380
	November 20, 2012		4-Dec-12		$	0.025			$	378

Restructuring_Charges_Tables

Restructuring Charges (Tables)	12 Months Ended
	Dec. 31, 2013
Restructuring And Related Activities [Abstract]	'
Components of Company's Restructuring Charges	'
	The components of the restructuring charges are as follows:
		Year ended
		December 31, 2011
		(in thousands)
	Distributor termination charges	$	572
	Transfer of manufacturing equipment		446
	Employee severance costs		291
	Italian government loan and grant termination charge		79
	Non cash asset write-off		732
	Other		41
	Total	$	2,161
Activity Related to Accrued Restructuring Costs	'
	Activity related to accrued restructuring costs is as follows:
		Year ended December 31,
		2012		2011
	Balance at beginning of year	$	101	$	922
	Plus:
	Current year restructuring costs		—		2,161
	Less:
	Payment for termination of contractual obligations		—		572
	Payment of employee severance costs		101		680
	Payment related to transfer manufacturing equipment		—		446
	Payment of Italian loan and grant		—		469
	Other		—		83
	Non-cash fixed asset write-off		—		732
	Balance at end of year	$	—	$	101

Segment_and_EnterpriseWide_Dis1

Segment and Enterprise-Wide Disclosures (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Net Sales to Unaffiliated Customers by Geography	'
	Net sales to unaffiliated customers by country were as follows:
		Year ended December 31,
		2013		2012		2011
		(in thousands)
	United States	$	39,240	$	36,542	$	35,366
	Germany		6,939		5,647		7,276
	Japan		2,413		2,674		2,283
	Other countries		15,957		11,872		12,760
	Net sales	$	64,549	$	56,735	$	57,685
Total Property and Equipment Held by Geography	'
	Total property and equipment held by geography were as follows:
		As of December 31,
		2013		2012
		(in thousands)
	United States	$	5,391	$	4,162
	Germany		229		232
	Other countries		190		150
	Total property and equipment	$	5,810	$	4,544

Supplemental_Cash_Flow_Informa1

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2013
Supplemental Cash Flow Elements [Abstract]	'
Supplemental Cash Flow Information	'
	Supplemental disclosures of cash flow information are as follows:
		Year ended December 31,
		2013		2012		2011
		(in thousands)
	Cash paid for income taxes, net	$	1,019	$	544	$	717

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Rollforward of the Fair Value as Determined by Level 3	'
	The following table provides a rollforward of the fair value, as determined by Level 3 inputs, of the contingent consideration.
		Year ended
		December 31,  2013
		(in thousands)
	Beginning balance	$	—
	Additions		42
	Payments		—
	Change in fair value included in earnings		57
	Ending balance	$	99

Quarterly_Financial_Data_Unaud1

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Data (Unaudited)	'
	Three months ended
	2013		March 31		June 30 (1)		September 30		December 31
			(in thousands, except per share data)
	Total net sales		$	15,382	$	15,951	$	15,300	$	17,916
	Gross profit			11,206		11,237		10,716		11,956
	Income from operations			1,123		1,447		776		1,172
	Net income			846		889		721		746
	Earnings per share
	Basic		$	0.06	$	0.06	$	0.05	$	0.05
	Diluted		$	0.05	$	0.06	$	0.05	$	0.05
			Three months ended
	2012		March 31		June 30		September 30		December 31
			(in thousands, except per share data)
	Total net sales		$	13,928	$	14,361	$	13,645	$	14,801
	Gross profit			9,870		10,545		10,015		10,438
	Income from operations			854		1,455		1,001		930
	Net income			386		824		663		698
	Earnings per share
	Basic		$	0.03	$	0.05	$	0.04	$	0.05
	Diluted		$	0.02	$	0.05	$	0.04	$	0.04
	-1	During the second quarter of 2013, we identified an error in our historic inventory valuation that resulted in an understatement of the periodic carrying amount of our inventory. We corrected this error which resulted in an understatement of cost of sales of $0.4 million and an overstatement of net income of $0.3 million in the three months ended June 30, 2013.

Significant_Accounting_Policie3

Significant Accounting Policies and Related Matters - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Concentration Risk [Line Items]	'	'	'
Remaining prior period of expiration for return of product	'18 months	'	'
Remaining prior period of expiration for return of product for hospital customers	'12 months	'	'
Maximum number of days for product return of shipment	'30 days	'	'
Cash and cash equivalents with maturity dates	'90 days	'	'
Accounts receivable	$10,590,000	$9,048,000	'
Impairment charges	'	'	83,000
Percentage of goodwill impairment	50.00%	'	'
Impairment charges of goodwill	0	0	0
Reclassification out of comprehensive income	0	0	'
Accumulated other comprehensive loss foreign currency translation adjustment losses	300,000	400,000	'
Commitment to a termination or exit plan	'12 months	'	'
Minimum [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Intangible assets useful lives	'1 year	'	'
Maximum [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Intangible assets useful lives	'13 years	'	'
United States [Member] | Minimum [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Accounts receivable due period	'30 days	'	'
United States [Member] | Maximum [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Accounts receivable due period	'90 days	'	'
Europe [Member] | Minimum [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Accounts receivable due period	'90 days	'	'
Europe [Member] | Maximum [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Accounts receivable due period	'240 days	'	'
Italy [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Accounts receivable	1,200,000	'	'
Spain [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Accounts receivable	$500,000	'	'

Significant_Accounting_Policie4

Significant Accounting Policies and Related Matters - Summary of Advertising Costs (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accounting Policies [Abstract]	'	'	'
Advertising expense	$421	$717	$410

Significant_Accounting_Policie5

Significant Accounting Policies and Related Matters - Summary of Allowance for Doubtful Accounts and Sales Returns (Detail) (Allowance for Doubtful Accounts and Sales Returns [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Allowance for Doubtful Accounts and Sales Returns [Member]	'	'	'
Allowance For Doubtful Accounts And Sales Returns [Line Items]	'	'	'
Balance at Beginning of Period	$326	$211	$184
Additions Charged to Income	29	153	56
Deductions from Reserves	92	38	29
Balance at End of Period	$263	$326	$211

Significant_Accounting_Policie6

Significant Accounting Policies and Related Matters - Summary of Property and Equipment (Detail)	12 Months Ended
	Dec. 31, 2013
Computers and Equipment [Member] | Maximum [Member]	'
Property Plant And Equipment Estimated Useful Lives [Line Items]	'
Useful Life	'5 years
Computers and Equipment [Member] | Minimum [Member]	'
Property Plant And Equipment Estimated Useful Lives [Line Items]	'
Useful Life	'3 years
Machinery and Equipment [Member] | Maximum [Member]	'
Property Plant And Equipment Estimated Useful Lives [Line Items]	'
Useful Life	'10 years
Machinery and Equipment [Member] | Minimum [Member]	'
Property Plant And Equipment Estimated Useful Lives [Line Items]	'
Useful Life	'3 years
Leasehold Improvements [Member]	'
Property Plant And Equipment Estimated Useful Lives [Line Items]	'
Estimated useful life	'The shorter of its useful life or lease term

Significant_Accounting_Policie7

Significant Accounting Policies and Related Matters - Computation of Basic and Diluted Net Income Per Share (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Basic:	'	'	'	'	'	'	'	'	'	'	'
Net income available for common stockholders	$746	$721	$889	$846	$698	$663	$824	$386	$3,202	$2,571	$2,143
Weighted average shares outstanding	'	'	'	'	'	'	'	'	15,317	15,194	15,458
Basic earnings per share	$0.05	$0.05	$0.06	$0.06	$0.05	$0.04	$0.05	$0.03	$0.21	$0.17	$0.14
Diluted:	'	'	'	'	'	'	'	'	'	'	'
Net income available for common stockholders	$746	$721	$889	$846	$698	$663	$824	$386	$3,202	$2,571	$2,143
Weighted-average shares outstanding	'	'	'	'	'	'	'	'	15,317	15,194	15,458
Common stock equivalents, if dilutive	'	'	'	'	'	'	'	'	447	444	531
Shares used in computing diluted earnings per common share	'	'	'	'	'	'	'	'	15,764	15,638	15,989
Diluted earnings per share	$0.05	$0.05	$0.06	$0.05	$0.04	$0.04	$0.05	$0.02	$0.20	$0.16	$0.13
Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive	'	'	'	'	'	'	'	'	373	549	355

Acquisitions_and_Divestitures_1

Acquisitions and Divestitures - Additional Information (Detail) (USD $)

12 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Aug. 31, 2013

Jul. 31, 2013

Jun. 02, 2010

Jun. 30, 2012

Dec. 31, 2013

Jun. 01, 2010

Jun. 30, 2012

Jun. 30, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2011

Aug. 31, 2011

Jul. 06, 2011

Jul. 31, 2013

Oct. 31, 2012

Oct. 31, 2013

Aug. 31, 2013

Jul. 31, 2013

Oct. 31, 2012

Dec. 31, 2012

Oct. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Oct. 31, 2013

Dec. 31, 2013

Jul. 31, 2013

Dec. 31, 2013

Aug. 31, 2013

Jul. 31, 2013

Aug. 31, 2013

Dec. 31, 2013

Oct. 31, 2013

Dec. 31, 2013

OptiLock Implantable Port [Member]

OptiLock Implantable Port [Member]

OptiLock Implantable Port [Member]

OptiLock Implantable Port [Member]

TAArget and UniFit Stent Grafts [Member]

TAArget and UniFit Stent Grafts [Member]

TAArget and UniFit Stent Grafts [Member]

TAArget and UniFit Stent Grafts [Member]

Endologix Stent Grafts [Member]

Endologix Stent Grafts [Member]

Endologix Stent Grafts [Member]

Non-compete Agreement [Member]

XenoSure [Member]

XenoSure [Member]

XenoSure [Member]

XenoSure [Member]

XenoSure [Member]

XenoSure [Member]

Schaublin [Member]

Schaublin [Member]

Schaublin [Member]

TryTech [Member]

Medistim [Member]

Medistim [Member]

Clinical Instruments [Member]

Clinical Instruments [Member]

Clinical Instruments [Member]

Clinical Instruments [Member]

InaVein LLC [Member]

InaVein LLC [Member]

Tag Medical Pty Ltd [Member]

Tag Medical Pty Ltd [Member]

Non-compete Agreement [Member]

Non-compete Agreement [Member]

Non-compete Agreement [Member]

Non-compete Agreement [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase price for acquisition of assets and rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4,600,000

'

'

'

'

'

$200,000

'

'

$100,000

$200,000

'

'

$1,100,000

'

'

$2,500,000

'

$200,000

'

Acquisition date of assets and rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31-Oct-12

'

1-Jan-13

'

1-Apr-13

'

1-Jan-14

'

30-Jul-13

'

'

30-Aug-13

'

'

1-Jan-14

Cash paid for assets purchased

3,291,000

4,373,000

1,151,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,300,000

'

'

'

'

'

'

'

'

'

'

'

'

900,000

'

'

2,100,000

'

'

'

Cash paid for manufacturing and distribution rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,800,000

'

'

'

'

'

'

'

'

'

'

'

600,000

'

'

'

'

700,000

'

'

Maximum goodwill deductible for tax purposes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'15 years

'

'

'

'

'

'

'

'

'

'

'

'15 years

'

'

'

'

'15 years

'

'

Intangible assets

'

'

'

1,143,000

322,000

'

'

'

'

'

'

'

'

'

'

'

95,000

2,756,000

'

1,143,000

322,000

306,000

'

100,000

'

'

100,000

'

'

300,000

'

'

'

1,100,000

'

'

'

Balance payable to Clinical Instruments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

400,000

'

'

'

Acquisition-related contingent consideration

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,400,000

'

'

'

Fair value of contingent consideration

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

42,000

'

'

General and administrative expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

57,000

'

'

Transition services as selling expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

20,000

'

'

'

'

'

'

'

'

'

'

Weighted-average amortization period for acquired intangible assets

'6 years 6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'7 years

'3 years

'

'3 years 6 months

'

'

'5 years

'5 years

'

'

'

'4 years 9 months 18 days

Purchase price installments description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The purchase price was paid in three equal installments in October 2012, January 2013, and January 2014.

'

'

'The purchase price is due in three equal installments with payments made in December 2012 and March 2013 with the final payment due in March 2014.

'The purchase price is due in three installments with payments made in October 2013 and January 2014 with the final payment due in December 2014.

'.

'

'

'

'

'

'

'The purchase price is due in three installments with payments made in November 2013 and January 2014 and the final payment due in December 2014

'

Agreement date of sale of event

'

'

'

'

'

'

'

1-Jun-10

'

'

'

30-Jun-11

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of product line

'

'

'

'

'

200,000

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payment terms due

'

'

'

'

'

'

'

'

30,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Wrote-off balance under insolvency protection law

'

'

'

'

'

'

52,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Promissory note received from sale of product line

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest on promissory note

'

'

'

'

'

'

'

'

'

7.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated fair value of promissory note receivable, other long term assets

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net charge, recorded in cost of sales

'

'

'

'

'

'

'

'

'

'

'

'

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Receivables on initial promissory note payment

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding promissory note balance

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain on divestiture

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain upon termination of distribution agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Termination of distribution agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Date of early termination agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6-Jul-11

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquisitions_and_Divestitures_2

Acquisitions and Divestitures - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Detail) (USD $)	Dec. 31, 2013	Aug. 31, 2013	Jul. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Aug. 31, 2013	Jul. 31, 2013	Oct. 31, 2012
In Thousands, unless otherwise specified						XenoSure [Member]	XenoSure [Member]	XenoSure [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Current assets	'	'	'	'	'	$670	$169	$12
Property and equipment, net	'	'	'	'	'	154	'	'
Intangible assets	'	1,143	322	'	'	1,143	322	2,756
Goodwill	15,031	'	'	13,749	11,917	668	614	1,832
Total assets acquired	'	'	'	'	'	2,635	1,105	4,600
Total liabilities assumed	'	'	'	'	'	-100	'	'
Acquisition cost	'	'	'	'	'	$2,535	$1,105	$4,600

Acquisitions_and_Divestitures_3

Acquisitions and Divestitures - Acquired Intangible Assets and Related Estimated Useful Lives (Detail) (USD $)	12 Months Ended							1 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Aug. 31, 2013	Jul. 31, 2013	Jul. 31, 2013	Aug. 31, 2013	Jul. 31, 2013	Oct. 31, 2012	Oct. 31, 2012	Oct. 31, 2012
				Non-compete Agreement [Member]	XenoSure [Member]	XenoSure [Member]	XenoSure [Member]	XenoSure [Member]	XenoSure [Member]
								Patents [Member]	Non-compete Agreement [Member]
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'	'	'	'
Allocated fair value	'	$1,143	$322	$95	$1,143	$322	$2,756	$2,450	$306
Weighted average useful life	'6 years 6 months	'	'	'	'	'	'	'13 years	'5 years

Acquisition_and_Divestitures_A

Acquisition and Divestitures - Acquired Intangible Assets and Related Estimated Useful Lives (Detail) (USD $)

12 Months Ended

1 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Aug. 31, 2013

Jul. 31, 2013

Jul. 31, 2013

Jul. 31, 2013

Aug. 31, 2013

Jul. 31, 2013

Aug. 31, 2013

Aug. 31, 2013

Aug. 31, 2013

Jul. 31, 2013

Aug. 31, 2013

Jul. 31, 2013

Aug. 31, 2013

Jul. 31, 2013

Aug. 31, 2013

Jul. 31, 2013

Aug. 31, 2013

Non-compete Agreement [Member]

Technology [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Non Compete Agreement [Member]

Trade Name [Member]

Technology [Member]

Clinical Instruments [Member]

Clinical Instruments [Member]

Clinical Instruments [Member]

Clinical Instruments [Member]

Clinical Instruments [Member]

Clinical Instruments [Member]

Clinical Instruments [Member]

Clinical Instruments [Member]

Non-compete Agreement [Member]

Non-compete Agreement [Member]

Technology [Member]

Technology [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Trade Name [Member]

Acquired Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Allocated fair value

'

$1,143

$322

$95

$147

$556

$80

$70

$163

$354

$300

'

'

'

'

'

'

'

Weighted average useful life

'6 years 6 months

'

'

'

'

'

'

'

'

'

'

'5 years

'5 years

'6 years

'6 years

'7 years

'6 years

'8 years

Inventory_Summary_of_Inventory

Inventory - Summary of Inventory (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$3,647	$2,471
Work-in-process	2,949	2,084
Finished products	6,659	6,304
Total inventory	$13,255	$10,859

Inventory_Additional_Informati

Inventory - Additional Information (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Inventory on consignment	$0.70	$0.70

Property_and_Equipment_Summary

Property and Equipment - Summary of Property and Equipment (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Gross property and equipment	$13,043	$10,763
Less accumulated depreciation	-7,233	-6,219
Property and equipment, net	5,810	4,544
Computers and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross property and equipment	2,369	2,196
Machinery and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross property and equipment	6,570	5,599
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross property and equipment	$4,104	$2,968

Property_and_Equipment_Depreci

Property and Equipment - Depreciation Expense (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property Plant And Equipment [Abstract]	'	'	'
Depreciation expense	$1,573	$1,319	$1,047

Goodwill_and_Other_Intangibles2

Goodwill and Other Intangibles - Goodwill (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Goodwill And Intangible Assets Disclosure [Abstract]	'	'
Goodwill, Beginning Balance	$13,749	$11,917
Additions for acquisitions	1,282	1,832
Goodwill, Ending Balance	$15,031	$13,749

Goodwill_and_Other_Intangibles3

Goodwill and Other Intangibles - Components of Other Intangibles (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	$10,899	$8,695
Accumulated Amortization	4,755	3,504
Net Carrying Value of Intangible Assets	6,144	5,191
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	5,679	5,108
Accumulated Amortization	1,932	1,339
Net Carrying Value of Intangible Assets	3,747	3,769
Trademarks and Technology Licenses [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	1,414	1,157
Accumulated Amortization	935	821
Net Carrying Value of Intangible Assets	479	336
Customer Relationships [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	2,835	1,757
Accumulated Amortization	1,441	1,001
Net Carrying Value of Intangible Assets	1,394	756
Other Intangible Assets [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	971	673
Accumulated Amortization	447	343
Net Carrying Value of Intangible Assets	$524	$330

Goodwill_and_Other_Intangibles4

Goodwill and Other Intangibles - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'
Weighted-average amortization period for intangibles	'6 years 6 months
Maximum [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Intangible assets useful lives	'13 years
Minimum [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Intangible assets useful lives	'1 year

Goodwill_and_Other_Intangibles5

Goodwill and Other Intangibles - Amortization Expense Included in General and Administrative Expense (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Goodwill And Intangible Assets Disclosure [Abstract]	'	'	'
Amortization expense	$1,220	$915	$990

Goodwill_and_Other_Intangibles6

Goodwill and Other Intangibles - Estimated Amortization Expense for Each of Five Succeeding Fiscal Years (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Goodwill And Intangible Assets Disclosure [Abstract]	'
Amortization Expense, Fiscal Year 2014	$1,414
Amortization Expense, Fiscal Year 2015	1,015
Amortization Expense, Fiscal Year 2016	870
Amortization Expense, Fiscal Year 2017	612
Amortization Expense, Fiscal Year 2018	$497

Financing_Arrangements_Additio

Financing Arrangements - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2011
	Installment
Debt Disclosure [Abstract]	'	'
Number of annual installment of loan payment	10	'
Percentage of Interest rate on loan	0.74%	'
Restructuring charges related to additional interest and penalties charges	'	$0.10
Final payment made to Italian government	'	$0.50

Accrued_Expenses_Accrued_Expen

Accrued Expenses - Accrued Expenses (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Payables And Accruals [Abstract]	'	'
Compensation and related taxes	$4,710	$3,860
Income and other taxes	885	963
Professional fees	428	521
Other	1,970	1,433
Total	$7,993	$6,777

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Commitments And Contingencies Disclosure [Abstract]	'	'
Assets held under capital leases	$0	$0
Commitments to purchase inventory	$4,400,000	'
Purchase commitments inventory expire year	'2015	'

Commitments_and_Contingencies_2

Commitments and Contingencies - Summary of Rent Expenses (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Commitments And Contingencies Disclosure [Abstract]	'	'	'
Rent expense	$1,264	$1,030	$1,182

Commitments_and_Contingencies_3

Commitments and Contingencies - Minimum Rental Commitments Under All Non-Cancelable Operating Leases with Initial or Remaining Terms of More Than One Year (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]	'
Operating leases, Fiscal Year 2014	$1,159
Operating leases, Fiscal Year 2015	1,119
Operating leases, Fiscal Year 2016	914
Operating leases, Fiscal Year 2017	689
Operating leases, Fiscal Year 2018	802
Operating leases, Thereafter	$4,075

Income_Taxes_Income_Loss_Befor

Income Taxes - Income (Loss) Before Income Taxes (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
United States	$4,692	$3,918	$3,511
Foreign	-364	75	241
Income before income taxes	$4,328	$3,993	$3,752

Income_Taxes_The_Provision_Ben

Income Taxes - The Provision (Benefit) for Income Taxes (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current:	'	'	'
Federal	$504	$881	$309
State	143	100	9
Foreign	192	154	132
Current, Total	839	1,135	450
Deferred:	'	'	'
Federal	1,968	503	831
State	-84	12	116
Foreign	-1,597	-228	212
Deferred, Total	287	287	1,159
Provision for income taxes	$1,126	$1,422	$1,609

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended				1 Months Ended		12 Months Ended			12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
					Subsequent Event [Member]	France [Member]	Spain [Member]	Italy [Member]	Sweden [Member]	Switzerland [Member]	Other Countries [Member]
Income Tax Examination [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Unrecognized tax benefits exclusive of interest and penalties, gross	$111,000	$321,000	$329,000	$277,000	'	'	'	'	'	'	'
Statute of limitations expiration period	'Through 2017	'	'	'	'	'	'	'	'	'	'
Foreign deferred tax assets and state credits	969,000	3,053,000	'	'	'	'	'	'	'	'	'
Net operating loss carryforwards	2,190,000	2,561,000	'	'	'	3,900,000	1,500,000	1,100,000	300,000	300,000	100,000
Net operating loss carryforwards, Expiration date	'	'	'	'	'	'	'2029	'	'	'2019	'
Federal and state tax credits relate to excess stock compensation deductions	100,000	'	'	'	'	'	'	'	'	'	'
Federal and state tax credit carryforwards	900,000	'	'	'	'	'	'	'	'	'	'
Federal and state tax credit carryforwards, expiration date	'2023	'	'	'	'	'	'	'	'	'	'
Undistributed earnings	1,400,000	'	'	'	'	'	'	'	'	'	'
Deferred tax liability	500,000	'	'	'	'	'	'	'	'	'	'
Additional U.S. tax credits recognized	$200,000	'	'	'	'	'	'	'	'	'	'
Income tax examination period	'	'	'	'	'the German tax authority notified our German subsidiary that the tax years 2009 through 2012 would be audited.	'	'	'	'	'	'

Income_Taxes_Reconciliation_of

Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Unrecognized tax benefits at the beginning of year	$321	$329	$277
Additions for tax positions of current year	'	'	52
Additions for tax positions of prior years	'	6	'
Reductions for lapses of the applicable statutes of limitations	-210	-14	'
Unrecognized tax benefits at the end of the year	$111	$321	$329

Income_Taxes_Deferred_Taxes_De

Income Taxes - Deferred Taxes (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred tax assets:	'	'
Inventory	$824	$772
Net operating loss carryforwards	2,190	2,561
Tax credit carryforwards	551	555
Reserves and accruals	313	263
Intangible assets	1,102	916
Stock options	203	326
Other	38	288
Total deferred tax assets	5,221	5,681
Deferred tax liabilities:	'	'
Property and equipment	-742	-692
Goodwill	-2,727	-2,374
Foreign branch deferred offset	-1,735	-146
Other	'	-26
Total deferred tax liabilities	-5,204	-3,238
Net deferred tax assets before valuation allowance	17	2,443
Valuation allowance	-969	-3,053
Net deferred tax liability	-952	-610
Deferred tax classification	'	'
Short-term deferred tax asset	932	850
Short-term deferred tax liability	-38	-60
Net short-term deferred tax asset	894	790
Long-term deferred tax asset	1,615	273
Long-term deferred tax liability	-3,461	-1,673
Net long-term deferred tax liability	-1,846	-1,400
Net deferred tax liability	($952)	($610)

Income_Taxes_Reconciliation_of1

Income Taxes - Reconciliation of the Federal Statutory Rate to Effective Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Federal statutory rate	34.00%	34.00%	34.00%
State tax, net of federal benefit	0.40%	2.30%	1.70%
Effect of foreign taxes	-4.10%	-4.90%	-1.60%
Subpart F income	2.20%	2.10%	2.40%
Valuation allowance	-38.20%	-6.60%	3.60%
Foreign deferred tax liability offset	36.10%	3.20%	0.00%
Manufacturing deduction	-2.90%	-3.50%	-0.70%
Research & development tax credits	-8.00%	0.60%	0.70%
Stock options	3.60%	3.40%	3.00%
Uncertain tax positions	-5.10%	-0.40%	1.90%
Italian permanent differences	5.20%	4.90%	0.00%
Other permanent differences	3.00%	4.10%	1.40%
Other	-0.20%	-3.80%	-3.50%
Effective tax rate	26.00%	35.40%	42.90%

Income_Taxes_Summary_of_Tax_Ye

Income Taxes - Summary of Tax Years Subject to Examination in Most Significant Tax Jurisdictions (Detail)	12 Months Ended
	Dec. 31, 2013
United States [Member]	'
Income Tax Examination [Line Items]	'
Income tax year under examination	'2010 and forward
Foreign [Member]	'
Income Tax Examination [Line Items]	'
Income tax year under examination	'2007 and forward

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	12 Months Ended				0 Months Ended	12 Months Ended		12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Feb. 20, 2014	Dec. 31, 2013	Jun. 14, 2012	Dec. 31, 2013	Jun. 14, 2012
				Common Stock [Member]	Subsequent Event [Member]	Maximum [Member]	Maximum [Member]	Minimum [Member]	Minimum [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'	'	'	'
Common stock, shares authorized	37,000,000	37,000,000	'	'	'	'	100,000,000	'	37,000,000
Preferred stock, shares authorized	3,000,000	3,000,000	'	'	'	'	5,000,000	'	3,000,000
Shares of common stock purchased	1,688,702	'	'	'	'	'	'	'	'
Incentive stock options vest	'	'	'	'	'	'5 years	'	'4 years	'
Expected term	'Not exceed ten years	'	'	'	'	'	'	'	'
Aggregate purchase price	3,000,000	'	'	'	'	'	'	'	'
Total number of shares currently authorized for stock award plans	4,618,003	'	'	'	'	'	'	'	'
Number of shares remain available for grant	783,012	'	'	'	'	'	'	'	'
Further option grants	$0	'	'	'	'	'	'	'	'
Fair values of RSUs, vested	800,000	700,000	900,000	'	'	'	'	'	'
Unamortized portion of share-based compensation expense	2,600,000	'	'	'	'	'	'	'	'
RSUs outstanding over a weighted-average period	'3 years 4 months 24 days	'	'	'	'	'	'	'	'
Repurchase of common stock	'	'	'	10,000,000	'	'	'	'	'
Cash dividend on common stock per share	'	'	'	'	$0.04	'	'	'	'
Dividend payment date	'	'	'	'	3-Apr-14	'	'	'	'
Dividends payment amount	'	'	'	'	$500,000	'	'	'	'
Dividend record date	'	'	'	'	20-Mar-14	'	'	'	'

Stockholders_Equity_Fair_Value

Stockholder's Equity - Fair Value of Employee Stock Options Using Weighted Average Assumptions (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Equity [Abstract]	'	'	'
Dividend yield	1.80%	1.60%	1.10%
Volatility	57.80%	61.80%	66.10%
Risk-free interest rate	1.50%	0.60%	1.40%
Weighted average expected option term (in years)	'5 years 6 months	'5 years 6 months	'4 years 9 months 18 days
Weighted average fair value per share of options granted	$3.01	$2.91	$3.57
Aggregate intrinsic value of options exercised	$1,009,726	$340,678	$321,584

Stockholders_Equity_Summary_of

Stockholder's Equity - Summary of Option Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Equity [Abstract]	'	'	'
Number of Shares, Balance outstanding at beginning	2,012,060	'	'
Number of Shares, Granted	367,277	'	'
Number of Shares, Exercised	-307,425	'	'
Number of Shares, Canceled / Expired	-209,112	'	'
Number of Shares, Balance outstanding at ending	1,862,800	2,012,060	'
Number of Shares, Vested and exercisable	1,002,215	'	'
Number of Shares, Expected to vest	639,094	'	'
Number of Shares, Total	1,641,309	'	'
Weighted Average Exercise Price, Balance outstanding at beginning	$5.64	'	'
Weighted Average Exercise Price, Granted	$6.92	'	'
Weighted Average Exercise Price, Exercised	$3.96	'	'
Weighted Average Exercise Price, Canceled / Expired	$8.84	'	'
Weighted Average Exercise Price, Balance outstanding at ending	$5.81	$5.64	'
Weighted Average Exercise Price, Vested and exercisable	$5.70	'	'
Weighted Average Exercise Price, Expected to vest	$4.57	'	'
Weighted Average Remaining Contractual Term	'4 years 9 months 26 days	'4 years 5 months 19 days	'
Weighted Average Remaining Contractual Term	'4 years 9 months 26 days	'4 years 5 months 19 days	'
Weighted Average Remaining Contractual Term, Vested and exercisable	'4 years 9 months 26 days	'	'
Weighted Average Remaining Contractual Term, Expected to vest	'4 years 7 months 17 days	'	'
Aggregate Intrinsic Value, Beginning Balance outstanding	$2,154,440	'	'
Aggregate Intrinsic Value, Exercised	1,009,726	340,678	321,584
Aggregate Intrinsic Value, Ending Balance outstanding	4,815,870	2,154,440	'
Aggregate Intrinsic Value, Vested and exercisable	$3,482,730	'	'

Stockholders_Equity_Summary_of1

Stockholder's Equity - Summary of Option Activity (Parenthetical) (Detail) (USD $)	Dec. 31, 2013
Equity [Abstract]	'
Closing price of stock	$8.01

Stockholders_Equity_Summary_of2

Stockholder's Equity - Summary of RSU Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Balance outstanding at the beginning, Shares	278,931
Shares Granted	117,873
Shares Vested	-112,284
Shares Canceled	-30,223
Balance outstanding at the ending, shares	254,297
Weighted Average Grant Date Fair Value, Beginning Balance	$5.30
Weighted Average Grant Date Fair Value, Granted	$6.67
Weighted Average Grant Date Fair Value, Vested	$4.37
Weighted Average Grant Date Fair Value, Canceled	$6.04
Weighted Average Grant Date Fair Value, Ending Balance	$6.25

Stockholders_Equity_Summary_of3

Stockholder's Equity - Summary of Repurchases (Detail) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Aggregage purchase price	$373	$2,021	$2,213
Restricted Common Stock Awards [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Shares of common stock repurchased	41,259	42,991	'
Per share repurchase price	$6.90	$6.11	'
Aggregage purchase price	$284,583	$262,719	'

Stockholders_Equity_ShareBased

Stockholder's Equity - Share-Based Compensation Expense (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Schedule of Trading Securities and Other Trading Assets [Line Items]	'	'	'
Total stock-based compensation	$1,253	$1,213	$1,097
Stock Option Awards to Employees [Member]	'	'	'
Schedule of Trading Securities and Other Trading Assets [Line Items]	'	'	'
Total stock-based compensation	789	692	591
Restricted Common Stock Awards [Member]	'	'	'
Schedule of Trading Securities and Other Trading Assets [Line Items]	'	'	'
Total stock-based compensation	$464	$521	$506

Stockholders_Equity_Stock_Repu

Stockholders' Equity - Stock Repurchase Activity (Detail) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Equity, Class of Treasury Stock [Line Items]	'	'	'
Total purchased, Total	$373	$2,021	$2,213
Share Repurchase Plan [Member]	'	'	'
Equity, Class of Treasury Stock [Line Items]	'	'	'
Shares repurchased, Shares	15,323	304,846	300,326
Total purchased, Total	$88	$1,759	$1,904

Stockholders_Equity_Dividend_A

Stockholders' Equity - Dividend Activity (Detail) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

In Thousands, except Per Share data, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Feb. 24, 2011

Dec. 31, 2013

Apr. 03, 2013

Feb. 24, 2011

Dec. 31, 2013

Jun. 05, 2013

Feb. 24, 2011

Dec. 31, 2013

Sep. 04, 2013

Feb. 24, 2011

Dec. 31, 2013

Dec. 04, 2013

Feb. 24, 2011

Dec. 31, 2012

Apr. 03, 2012

Feb. 24, 2011

Dec. 31, 2012

Jun. 04, 2012

Feb. 24, 2011

Dec. 31, 2012

Aug. 31, 2012

Feb. 24, 2011

Dec. 31, 2012

Dec. 04, 2012

Installment 1 FY 2013 [Member]

Installment 1 FY 2013 [Member]

Installment 1 FY 2013 [Member]

Installment 2 FY 2013 [Member]

Installment 2 FY 2013 [Member]

Installment 2 FY 2013 [Member]

Installment 3 FY 2013 [Member]

Installment 3 FY 2013 [Member]

Installment 3 FY 2013 [Member]

Installment Four Fy Two Zero One Three [Member]

Installment Four Fy Two Zero One Three [Member]

Installment Four Fy Two Zero One Three [Member]

Installment 1 FY 2012 [Member]

Installment 1 FY 2012 [Member]

Installment 1 FY 2012 [Member]

Installment 2 FY 2012 [Member]

Installment 2 FY 2012 [Member]

Installment 2 FY 2012 [Member]

Installment 3 FY 2012 [Member]

Installment 3 FY 2012 [Member]

Installment 3 FY 2012 [Member]

Installment 4 FY 2012 [Member]

Installment 4 FY 2012 [Member]

Installment 4 FY 2012 [Member]

Dividends Payable [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Record Date

'

'

'

'

20-Mar-13

'

'

22-May-13

'

'

21-Aug-13

'

'

20-Nov-13

'

'

20-Mar-12

'

'

18-May-12

'

'

17-Aug-12

'

'

20-Nov-12

'

Payment Date

'

'

'

'

3-Apr-13

'

'

5-Jun-13

'

'

4-Sep-13

'

'

4-Dec-13

'

'

3-Apr-12

'

'

4-Jun-12

'

'

31-Aug-12

'

'

4-Dec-12

'

Per Share Amount

$0.12

$0.10

$0.08

$0.03

'

'

$0.03

'

'

$0.03

'

'

$0.03

'

'

$0.03

'

'

$0.03

'

'

$0.03

'

'

$0.03

'

'

Dividend Payment

'

'

'

'

'

$457

'

'

$457

'

'

$460

'

'

$464

'

'

$381

'

'

$379

'

'

$380

'

'

$378

ProfitSharing_Plan_Additional_

Profit-Sharing Plan - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2011
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]	'	'
Vesting period of contributions	'6 years	'
Deferred Profit Sharing [Member]	'	'
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]	'	'
Contribution amount	$40,000	$100,000

Restructuring_Charges_Addition

Restructuring Charges - Additional Information (Detail) (USD $)

12 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2012

Dec. 31, 2011

Feb. 28, 2014

Mar. 31, 2014

Mar. 31, 2014

31-May-11

Dec. 31, 2011

31-May-11

Dec. 31, 2011

Dec. 31, 2011

Jun. 30, 2011

Jun. 30, 2011

Feb. 29, 2012

Dec. 31, 2011

Employee

Subsequent Event [Member]

Minimum [Member]

Maximum [Member]

Laguna Hills Facility [Member]

Laguna Hills Facility [Member]

Burlington [Member]

Burlington [Member]

Laguna Hills Manufacturing Facility Closing [Member]

Contract Termination with Spanish Distributor [Member]

Contract Termination with Danish Distributor [Member]

Biomateriali Manufacturing Facility Closing [Member]

Biomateriali Manufacturing Facility Closing [Member]

Scenario, Forecast [Member]

Scenario, Forecast [Member]

Employee

Employee

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring charges associated with the transfer of manufacturing equipment

'

$446,000

'

'

'

'

'

'

$300,000

$100,000

'

'

'

'

Restructuring charges related to deferred rent charges

'

'

'

'

'

'

'

'

'

'

'

'

'

700,000

Repayment of grants and loans

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

Cash paid out of severance charges

101,000

680,000

'

'

'

'

'

'

'

'

'

'

200,000

400,000

Final Payment

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

Employees terminated

'

6

'

'

'

7

'

'

'

'

'

'

'

'

Employees hired to staff facility

'

'

'

'

'

'

'

4

'

'

'

'

'

'

Severance Costs

'

291,000

'

200,000

400,000

'

33,000

'

'

'

'

'

'

'

Restructuring charges

'

$2,161,000

'

'

'

'

'

'

'

'

$500,000

$100,000

'

'

Percentage of reduction in work force

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

Restructuring_Charges_Componen

Restructuring Charges - Components of Company's Restructuring Charges (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2011
Reorganizations [Abstract]	'
Distributor termination charges	$572
Transfer of manufacturing equipment	446
Employee severance costs	291
Italian government loan and grant termination charge	79
Non cash asset write-off	732
Other	41
Total	$2,161

Restructuring_Charges_Activity

Restructuring Charges - Activity Related to Accrued Restructuring Costs (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2011
Reorganizations [Abstract]	'	'
Balance at beginning of year	$101	$922
Plus: Current year restructuring costs	'	2,161
Less: Payment for termination of contractual obligations	'	572
Less: Payment of employee severance costs	101	680
Less: Payment related to transfer manufacturing equipment	'	446
Less: Payment of Italian loan and grant	'	469
Less: Other	'	83
Less: Non-cash fixed asset write-off	'	732
Balance at end of year	'	$101

Segment_and_EnterpriseWide_Dis2

Segment and Enterprise-Wide Disclosures - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013
	Segment
Segment Reporting [Abstract]	'
Number of operating segments	1

Segment_and_EnterpriseWide_Dis3

Segment and Enterprise-Wide Disclosures - Net Sales to Unaffiliated Customers by Geography (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting Information [Line Items]	'	'	'
Net sales	$64,549	$56,735	$57,685
United States [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	39,240	36,542	35,366
Germany [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	6,939	5,647	7,276
Japan [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	2,413	2,674	2,283
Other Countries [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	$15,957	$11,872	$12,760

Segment_and_EnterpriseWide_Dis4

Segment and Enterprise-Wide Disclosures - Total Property and Equipment Held by Geography (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	$5,810	$4,544
United States [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	5,391	4,162
Germany [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	229	232
Other Countries [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	$190	$150

Supplemental_Cash_Flow_Informa2

Supplemental Cash Flow Information - Supplemental Cash Flow Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Supplemental Cash Flow Elements [Abstract]	'	'	'
Cash paid for income taxes, net	$1,019	$544	$717

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	Dec. 31, 2013
Level 1 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Cash equivalents in money market fund	$8,300,000
Recurring [Member] | Level 2 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Assets measured at fair value	$0

Fair_Value_Measurements_Rollfo

Fair Value Measurements - Rollforward of the Fair Value as Determined by Level 3 (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Beginning balance	'
Additions	42
Payments	'
Change in fair value included in earnings	57
Ending balance	$99

Quarterly_Financial_Data_Unaud2

Quarterly Financial Data (Unaudited) - Quarterly Financial Data (Unaudited) (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Total net sales	$17,916	$15,300	$15,951	$15,382	$14,801	$13,645	$14,361	$13,928	'	'	'
Gross profit	11,956	10,716	11,237	11,206	10,438	10,015	10,545	9,870	45,115	40,868	40,227
Income from operations	1,172	776	1,447	1,123	930	1,001	1,455	854	'	'	'
Net income	$746	$721	$889	$846	$698	$663	$824	$386	$3,202	$2,571	$2,143
Earnings per share	'	'	'	'	'	'	'	'	'	'	'
Basic	$0.05	$0.05	$0.06	$0.06	$0.05	$0.04	$0.05	$0.03	$0.21	$0.17	$0.14
Diluted	$0.05	$0.05	$0.06	$0.05	$0.04	$0.04	$0.05	$0.02	$0.20	$0.16	$0.13

Quarterly_Financial_Data_Unaud3

Quarterly Financial Data (Unaudited) - Quarterly Financial Data (Unaudited) (Parenthetical) (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2013
Cost of Sales [Member]	'
Restructuring Charges By Income Statement Location [Line Items]	'
Prior period adjustments	$0.40
Net Income [Member]	'
Restructuring Charges By Income Statement Location [Line Items]	'
Prior period adjustments	$0.30